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HIV-1 infected women in Europe
Abstract
This thesis aims to describe the wider impact of HIV infection on reproductive 
choices and pregnancy outcomes in HIV-infected women in Europe.
Characteristics of 403 HIV-infected women enrolled in a survey on reproductive 
choices are described. There was no evidence to suggest HIV-infected women 
have problems to conceive; maternal well-being, an uninfected partner and not 
having children yet were strongly associated with being pregnant.
Results from a laboratory-based descriptive study, including 57 pregnant women 
provide a biological explanation for HAART-associated premature delivery in HIV- 
infected women; cytokine patterns (IL2 and IL10) were analysed over three 
trimesters of pregnancy and in relation to gestational age at delivery.
Intrauterine growth (femur length, head and abdominal circumference) of infants 
born to 316 HIV infected mothers, compared to an uninfected population is 
reported. The average z-score of head circumference and femur length in HIV- 
infected women was below the reference (32th centile and 15th centile 
respectively), but the average z-score for abdominal circumference differs only 
marginally (49th centile).
In order to add one more piece of information in relation to maternal treatment and 
gestational age at delivery, birth-weight from a large European cohort was 
analysed and compared to the British standard. Mean z-scores decreased from - 
0.10 (46th centile), -0.13 (45th centile) and -0.30 (37th centile) throughout 
gestation indicating that children born to HIV infected mothers became smaller 
towards the end of pregnancy, and premature delivery in HAART-treated mothers 
was not associated to fetal distress.
Complications after delivery according to infection status of the mother and mode 
of delivery, were reported from a total of 250 HIV-status matched pairs delivered 
vaginally and from 158 by elective caesarean section. HIV-infected women 
suffered an increased risk of minor complications, but major complications only 
occurred in the caesarean section arm.
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LIST OF ABBREVIATIONS AND EXPLANATIONS
HIV/AIDS: the human immunodeficiency virus (HIV) is a frequently mutating
retrovirus that attacks the human immune system and which has been shown to 
cause acquired immune deficiency syndrome (AIDS).
LAV: The first AIDS cases were described in 1981. HIV was discovered and 
identified as the agent for AIDS by Luc Montagnier of France and Robert Gallo of 
the United States in 1983-1984. At the time, the virus was called Human T- 
Lymphotropic Virus type III (HTLV-III) or Lymphadenopathy-Associated Virus 
(LAV). In 1986, the genome of the virus was cloned and sequenced. The name 
HIV has been in use since 1986.
CCR5/ CXCR4: CCR5 is the chemokine receptor which HIV uses as a coreceptor 
to gain entry into macrophages. Certain strains of HIV target macrophages rather 
than T cells, because their envelope protein is configured such that it works best 
with CCR5 as a coreceptor - these strains are called macrophage-tropic. 
(Interestingly, macrophage-tropic strains tend not to be able to induce syncytia).
CCR5 is perhaps the most important of the known coreceptors for HIV, since the 
most commonly transmitted strains of HIV are strains that bind to CCR5 - so-called 
"R5" strains. CXCR4 (aka "fusin") and CXCR5 are both chemokine receptors. 
That is, they are proteins normally embedded in the membrane of a cell, which 
respond to the presence of chemokines outside the cell to trigger some kind of 
response within the cell.
HIV-1 is able to use either CXCR4 or CXCR5 as a co-receptor (CD4 being the 
main receptor) to facilitate binding and entry into T cells.
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About 10% of all Europeans carry a polymorphism of CCR5. People with this 
mutation (a 32 base pair deletion) have a very low risk of acquiring infection.
PCR: Polymerase Chain Reaction (PCR) is a biological molecular method for 
amplifying DNA without using a living organism.
RT: Reverse transcriptase is an enzyme used by all retroviruses and
retrotransposons that transcribes the genetic information from the virus or 
retrotransposon from RNA into DNA, which can integrate into the host DNA. 
Eukaryotes with linear DNA uses a variant of reverse transcriptase, called 
telomerase, with the RNA template contained in the enzyme itself. The enzyme 
collectively referred to as reverse transcriptase generally includes an RNA- 
dependent DNA polymerase and a DNA-dependent DNA polymerase, which work 
together to perform transcription in the reverse of the standard direction. Usually, 
transcription only runs from DNA to RNA, catalyzed by RNA polymerase. In 
addition to the transcription function, retroviral reverse transcriptase carries a 
RNase domain, which belongs to the RNase H family.
RT PCR: Reverse transcriptase is commonly used in the field of research to be 
able to apply the polymerase chain reaction technique to RNA. The classical PCR 
technique can only be applied to DNA strands, but with the help of reverse 
transcriptase, RNA can be transcribed into DNA making PCR analysis of RNA 
molecules possible. The technique is collectively called: Reverse Transcriptase 
Polymerase Chain Reaction (RT-PCR). Reverse transcriptase is also used to 
create cDNA libraries from mRNA. Since HIV uses reverse transcriptase, together 
with integrase, to infect human DNA with viral DNA, reverse transcriptase inhibitors 
are used to prevent this.
PBMC: peripheral blood mononuclear cells.
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RPMI 1640: Liquid classic cell culture media
Immune cells: Pathogens (viruses or bacteria) that escape antibody detection can 
enter and infect cells. The surface of infected cells changes, and this change is 
recognized by T cells. Cytotoxic T cells kill infected cells, preventing these cells 
from producing more pathogens. Cytotoxic T cells must interact with Helper T cells 
(Th) to regulate destruction of infected cells. Dendritic cells must activate CD4+ 
helper T cells before our bodies can produce B cells secreting pathogen specific 
antibodies or cytotoxic T cells (CTL) to destroy infected cells.
Natural Killers (NK) cells accumulate mostly in "secondary lymphoid tissues" - the 
tonsils, lymph nodes and spleen - after emerging from the bone marrow. There, the 
natural killer cells await activation (probably after stimulation by sentinel dendritic 
cells) before they react in two distinct modes. In one mode, they promptly secrete 
cytokines, chemical messenger proteins, which modulate emerging T and B 
immune cell responses. In the other, they become potent killers of tumors and 
virus-infected cells.
PHA: Phytohemoagglutinin induces cell activity , it can activates lymphocytes or 
different cell lines ( ex hematopoietic cells).
ENV: "envelope" the proteins derived from env are a surface (gp120) and a
transmembrane gp41 protein . They are located at the outer part of the virus 
particle and enable the virus to attach to and to fuse with the target cells to initiate 
the infectious cycle. The gene-product has a knoblike structure.
ELISA: (HIV enzyme immunoassay)
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X  A K Patient serum which contains antibodies. If the patient is HIV+, then 
this serum will contain antibodies to HIV, and those antibodies will bind to the HIV 
antigens on the plate.
Anti-human immunoglobulin coupled to an enzyme. This is the 
second antibody, and it binds to human antibodies.
A
w  Chromogen or substrate which changes color when cleaved by the 
enzyme attached to the second antibody.
HAART: highly active anti-retroviral therapy with a combination of drugs results in 
a dramatic reduction in viral levels. HAART coupled with improved treatments of 
HIV-related secondary infections has dramatically improved survival for HIV 
infected patients.
ART: Antiretroviral treatment
Positive Elisa test
Reverse
transcriptase
inhibitors
CD4 molecule
Protease'
inhibitors
— HIV
Integrase
^ n u w u i  rUSlOn / \
Mature *""* processing TlFusion/entry
HIV virion and assembly ^ in h ib ito rs
2
2
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HIV binds to CD4 cell surface molecules, entry into the cell also requires binding to 
co-receptors CXCR4 and CCR5). This step can be inhibited by fusion/entry 
inhibitors.
HIV is uncoated inside the cell and reverse transcriptase copies genomic RNA into 
DNA, making errors at a frequence of about one per replication cycle. Reverse 
transcriptase inhibitors were the first class of HIV inhibitors to be used as drugs.
Viral DNA can integrate into host DNA and become a part of the cellular genome. 
This step makes the infection irreversible, and may mean that eliminating the virus 
from an infected individual is not possible. Integrase inhibitors are designed to 
block this step of infection.
The virus uses cellular machinery to synthesize viral proteins. Several of these are 
long amino acid chains which must be cleaved by a specific viral protease before 
new viral particles can become active. Protease inhibitors block viral maturation 
at this step.
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Chapter 1 Women and HIV infection: an overview
“Women are increasingly affected, now making up nearly half of the 37.2 million 
adults living with HIV worldwide. The virus is spreading into the female population 
because it is more readily transmitted from men to women in sexual contact. The 
lower status of women and girls in many regions and their vulnerability to sexual 
exploitation by men are also cited as factors in their susceptibility to infection.”
"Strategies to address gender inequalities are urgently needed if we want a 
realistic chance at turning back the epidemic,"
Source: AIDS Epidemic Update 2004, the annual report by the Joint United 
Nations Programme on HIV/AIDS (UNAIDS) and the World Health Organization 
(WHO).
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1.1 Introduction
The rapid spread of the human immunodeficiency virus (HIV) across populations 
has been facilitated by the health-related and lifestyle changes which have taken 
place over the last three-quarters of a century. This started with the discovery and 
widespread use of penicillin and other antibiotics which provided a cure for most 
common sexually transmitted diseases, thereby changing the perception of sexual 
risk substantially (Browne 1970; WHO 1972). The use and increasing efficacy of 
contraceptives has also been key; the use of condoms started to become common 
amongst soldiers in the Second World War. Subsequently, the availability of 
hormonal contraceptives from the 1960s has had an additional major impact on 
sexual practice; with markedly decreased risk of pregnancy. Lifestyles have also 
changed substantially with easier long distance travelling allowing for more social 
migration and sexual mixing (Stigum, 1994; Lydie, 2004; Lurie, 2003)
The first evidence of AIDS in the developed world was related to groups of 
individuals who shared a common exposure risk (CDC, 1985). In the United 
States, sexually active homosexual men were among the first to be discovered with 
manifestations (Pneumocystis carinii pneumonia) of what is now known to have 
been HIV disease, followed by recipients of blood or blood products, injecting drug 
users, and ultimately children born to infected mothers.
The first cases of AIDS in children were reported in 1982 (Thomas 1984) and by 
the end of 1995, there were more than an estimated 1.5 million children with AIDS 
worldwide. The findings of three female half-siblings who had clinical and 
laboratory evidence for AIDS, whose mother had abnormal T-cell immunity strongly 
suggested vertical transmission of HIV during the perinatal period (Cowan 1984). 
However, although the presence of HIV in children and then their mothers was 
recognized fairly early on in the epidemic, it took longer, and prospective follow-up
17
studies of HIV infected pregnant women and their children, to understand that not 
all children born to HIV infected women are themselves infected. The HIV epidemic 
among children is closely linked to that in women, since the vast majority of paediatric 
infections are the result of vertical transmission from mother to infant. In order to 
estimate the number of children at risk of perinatally acquired infection, knowledge of 
both the prevalence of infection among women of childbearing age, and the rate of 
vertical transmission is required.
Women represent an increasing proportion of reported AIDS cases in Europe, and 
worldwide; now representing 47% of all young adults living with HIV and AIDS; this 
proportion had been steadily increasing over time (UNAIDS, 2004) (Figure 1.1). 
The characteristics of the HIV-infected women have changed since the start of the 
epidemic. HIV-infected women in Europe are now more likely to have acquired their 
infection heterosexually than through injecting drug use; they are having their children 
at increasingly older ages and are more likely to know that they are HIV-infected 
when they become pregnant.
In developing countries, the AIDS epidemic manifested itself quite differently, both 
because the HIV-related signs and symptoms were harder to identify because of 
other competing causes of morbidity and mortality and because the epidemic did 
not seem to be limited to “high-risk” groups and, instead, was more generalized . 
By the end of 2004, nearly 37 million people worldwide were living infected with 
HIV, of whom about 17.6 million were women; out of 610 thousand HIV-infected 
people living in Central and Western Europe, 160 thousand are women. 
(UNAIDS,2004). Globally, there are currently two HIV-infected women for every 
three infected men but it is expected that the number of new infections among 
women will equal those among men (Stover, 2004). However, the male-to-female 
ratio varies between countries: approximately equal numbers of male and female 
AIDS cases are already reported from sub-Saharan Africa, with an excess of
18
female cases (Figure 1.2) reported from some areas such as Uganda and in 
younger age groups. (Population Reference Bureau, 2003).
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Figure 1.1: Percent of adults (15-49) living with HIV who are female, 1985-2004(Source UNAIDS/WHO, 2004)
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Figure 1.2: Number of women and men living with HIV in sub-Saharan Africa, 1985-2004 (Source: UNAIDS/WHO, 2004)
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Initially, homosexual transmission was the main mode of acquisition of HIV in the 
USA, whilst in Europe it was injecting drug use (IDU), which was mainly a male 
phenomenon; consequently, the sex ratio among AIDS cases in these areas was 
skewed towards men. However, with adherence to health education messages 
among homosexuals and injecting drug users, especially in urban populations, the 
proportion of AIDS cases in homosexual men and IDUs has declined and, in 
parallel, there has been an increase in heterosexually acquired infections among 
men and women of reproductive age (EuroHIV, 2003) (Figure 1.3).
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Figure 1.3: HIV infections newly diagnosed by transmission group 1994-2003, Western Europe (Source: EuroHIV)
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1.2 Epidemiology of HIV infection in women
Changes in the therapeutic management of HIV disease, in particular, the 
increasing use of combinations of at least three antiretroviral drugs since 1996/7, 
have resulted in a significant improvement in AIDS-free survival (Mocroft, 2003) 
with larger numbers of women becoming pregnant while on combination therapy 
(Dorenbaum, 2002; European Collaborative Study, 2005) The number of HIV- 
infected women giving birth has been increasing constantly in the past decade. 
The identification of HIV-infected women prior to or during pregnancy or before 
delivery ensures the appropriate management of the woman and her child and the 
success of any intervention to reduce mother-to-child transmission will depend 
ultimately on the identification of HIV-infected women during pregnancy. The 
uptake of antenatal testing is nowadays highly variable across Europe and there is 
partial information (only from some countries) available to quantify how many HIV- 
infected women have been identified during pregnancy (Figure 1.4) (EuroHIV, 
2003). Recent reports show a shift in the characteristics of HIV-infected women 
who become pregnant, who are now most likely to be heterosexually infected and 
older than previously (European Collaborative Study 2005). This may lead both to 
a more difficult identification of these women through selective testing 
programmes, and to the higher risk of vertical transmission, despite the fact that 
more and more of these women seem to originate from African countries and are 
thus more easily identifiable. In Europe, a substantial number of HIV-infected 
women originate from a country where heterosexual transmission is frequent 
(mainly from sub-Saharan Africa) (Project Inform 2001; Fleischman 2004) having 
additional medical needs compared to their male counterparts, such as those 
relating to family planning and obstetric and gynaecological services.
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Figure 1.4: HIV prevalence surveys and routine diagnostic testing among pregnant women: HIV prevalence per 10,000, 
WHO European Region, 2000 (Source: EuroHIV)
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The use of interventions to reduce mother-to-child transmission on a population 
basis has been shown to have resulted in a decline in the number of new 
paediatric HIV infections in developed countries (Dorenbaum et al, 2002; Simpson 
et al, 2000; Mandelbrot et al 2001; Cooper et al, 2002) Despite this, nearly all the 
estimated 710,000 new HIV infections in children each year globally still result from 
mother-to-child transmission. Although over 90% of these infections occur in sub- 
Saharan countries where interventions are not available or not applied, a number 
of infants are still at risk of becoming congenitally infected in Europe, where the 
estimated prevalence of HIV infection among pregnant women ranges from 2.6 to 
less than 0.2 per 1000 livebirths.
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1.3 HIV acquisition in women
Transmission of HIV infection takes place through three main routes: sexual 
contact with an infected person, parenteral exposure to infected blood or blood 
products, and vertical transmission from mother to child.
The demographic characteristics of those newly infected with HIV are changing, 
and the proportion of incident and prevalent cases that are in women is increasing. 
Twenty percent of HIV-infected individuals in North America and Europe are female 
(UNAIDS 2004).
Women could be biologically more vulnerable to heterosexual acquisition of HIV 
infection than men, and for a long time the rate of male-to-female transmission has 
been considered nearly double that of female-to-male transmission of HIV. The 
risk per single receptive intercourse appears to be approximately 0.2-1%, but there 
are many factors which may increase this risk (Nicolosi, 1994, De Vincenzi, 1994, 
Vernazza, 1999). Furthermore, some women at risk of acquisition of infection are 
unable to require consistent male condom use, which provides effective protection 
against sexually transmitted diseases, including HIV.
Among European women with HIV (new infections), sexual transmission 
constitutes 40% of reported cases (EuroHIV, 2003). However, AIDS cases are not 
indicative of current trends of HIV infection in the general population, especially 
now that widespread use of effective antiretroviral therapy has made HIV a more 
chronic disease; information on trends on of newly HIV infected individuals 
represents better the current status of the epidemic.
Parenteral transmission includes that in illicit drug users exposed to infected blood, 
recipients of contaminated blood transfusions or other blood products, such as 
factor VIII used by haemophiliacs and patients infected in health care settings 
where there is inadequate sterilization of injecting equipment. HIV can spread very
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rapidly in illicit drug users, reflecting the efficiency of parenteral transmission. 
Information campaigns and needle exchanges have been relatively successful in 
Western Europe in reducing the infection rate through this mode, as evidenced by 
reports of stabilisation or even declines in the incidence of infection among IDUs. 
However, the increasing incidence of HIV infection among I DUs in Eastern Europe, 
especially Poland and the Ukraine, is of concern (UNAIDS, 2004). Many HIV- 
infected female IDUs also have sexual risk factors for HIV acquisition, including 
I DU sexual partners and the exchange of sex for drugs or money. It is therefore 
difficult to determine by which route women with high risk injecting and sexual 
behaviours acquired their HIV infection.
Vertical transmission will be discussed in Chapter 2. Other routes of transmission 
are of theoretical concern in the household setting, where close contact may occur 
between parent and child, or siblings, although epidemiological evidence for 
horizontal transmission within families is lacking (Shuster, 2005).
1.4 Factors facilitating HIV acquisition
Transmission of HIV infection can be influenced by several factors, including the 
quantity and infectivity of the virus, and the characteristics of the HIV-infected host.
There is an association between the quantity of virus transmitted and the risk of 
acquiring HIV infection (Roques, 1993; Royce, 1997). Several studies have found 
that HIV-infected persons may be more likely to transmit the infection when viral 
replication is high, both during the initial stage of infection (Palasanthiran, 1993) 
and at more advanced stages of HIV disease (Dyer 1998). People with high blood 
viral load are more likely to transmit HIV to recipients of blood, their sexual 
partners, and their offspring (Quinn, 2000; Vernazza, 1999). HIV has been 
quantified in semen (Coombs, 1998; Speck, 1999; Vernazza, 1997) and detected 
in female genital secretions (Ghys, 1997; Mostad, 1998), and virus in these
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locations may facilitate transmission. However, the association between infectivity 
and disease stage is not absolute; HIV-infected women may transmit virus to a 
first-born child but not to a second-born child (De Martino, 1991), and temporal 
studies of semen from HIV-infected men demonstrate fluctuating viral titers over 
time. Viral load can be low in plasma but high in semen or genital secretions, 
explaining the possibility of transmission from mothers with undetetectable viral 
load to the fetus.
Factors that decrease viral titers, including antiretroviral therapy, may decrease but 
not eliminate the risk of HIV transmission (Kovacs, 2001; Fiore, 2003; Garcia- 
Bujalance, 2004). Individuals receiving antiretroviral therapy have also shown 
reduced rates of HIV transmission to their sex partners (Musicco, 1994). Several 
studies have suggested that antiretroviral treatment reduces detection of HIV in 
female genital secretions (Cu Uvin, 1998) and the concentration of HIV in semen 
(Gilliam, 1997; Gupta, 1997), but most data are on the effect of antiretroviral 
therapy on plasma viral load.
Factors that increase the risk of exposure to blood, such as genital ulcer disease 
(Serwadda, 2003; Plummer, 1991), trauma during sexual contact, and 
menstruation of an HIV-infected woman during sexual contact (European Study 
Group, 1992; Kalichman, 2004) may all increase the risk of transmission.
The method of contraception also affects the likelihood of HIV transmission 
(Plummer, 1997). There is overwhelming evidence that the correct and consistent 
use of latex condoms protects both men and women against HIV. However, 
because of methodological difficulties in studies of contraceptive use and HIV 
transmission, it remains unclear whether the use of hormonal contraceptives, IDUs, 
and spermicides alters the risk of HIV transmission.
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Similarly, characteristics of the uninfected individual may increase the likelihood of 
infection for a given exposure to HIV. There is increasing evidence that genetic or 
immunological factors of the host may protect against HIV infection. For example, 
individuals who are homozygous for a nullallele of CCR5 are relatively resistant to 
sexually transmitted infection with HIV, indicating an important, though not 
absolute, role for this receptor in viral transmission (Lucotte, 1998).
1.5 Natural history of HIV infection
HIV is a retrovirus belonging to the lentivirus family and was initially known as 
lymphadenopathy-associated virus (LAV) and human T-cell lymphotropic virus type 
III (HTLV-III). REF Cells expressing the surface antigen complex CD4, the main 
receptor for HIV, are the major targets for the virus, the most important being the 
central regulatory cells of the immune system, the T-helper lymphocytes (CD4 
cells). HIV enters the target cells and integrates into the nucleus following reverse 
transcription of viral RNA to DNA. Viral replication may then take place, although 
some infected cells remain in a latent state of infection and continue to circulate in 
the body as viral reservoirs.
Cell death in a variety of human cell lines results from HIV infection. T-helper 
lymphocytes (also known as CD4 cells) are a major target of viral infection, and 
circulating CD4 cells are killed off in peripheral blood in the majority of infected 
individuals not taking antiretroviral therapy. Severe CD4 cell depletion is not 
common in individuals free of HIV infection and is usually associated with severe 
illnesses, for example chemotherapy-induced leukopenia (Aldrich, 2000).
Individuals infected with HIV who do not receive antiretroviral therapy suffer 
immunological damage and loss of an effective immune response to specific 
opportunistic pathogens and tumours and will ultimately become symptomatic of, 
and be classified with, AIDS. There is a classification process that is used to
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standardize clinical evaluation, clinical interventions and therapies. In the 
developed world, the system for classifying HIV infection and AIDS which is most 
commonly used is that published by the United States Centers for Disease Control 
and Prevention in 1993 (CDC, 1993).
Table 1.1: The 1993 Revised CDC Classification System for HIV Infection
Clinical categories*
A B C
CD4+ T cell 
categories 
(cells/cu mm)
Asymptomatic, 
acute (primary) 
HIV or PGL**
Symptomatic, 
not A or C
AIDS Indicator
(1) >=500 A1 B1 C1
(2) 200-499 A2 B2 C2
(3) <200 A3 B3 C3
* Persons in categories A3, B3, C1, C2, and C3 have AIDS under the 1993 
surveillance case definition.
** PGL = persistent generalized lymphadenopathy. Clinical Category A includes 
acute (primary) HIV infection.
A large number of laboratory tests have been evaluated as prognostic indicators for 
disease progression in HIV infection. Generally, tests can be divided into three 
main groups: (i) measures of HIV replication (specific to HIV infection), (ii) 
measures of immune function (relatively specific to HIV infection), and (iii) 
measures of inflammation (generally not specific to HIV infection). HIV RNA 
quantification, performed on fresh or frozen plasma or serum, is a powerful and 
accurate prognostic indicator for progression of HIV infection and is uniquely useful 
in determining response to antiretroviral therapy (Saag, 1996). In general, the best 
measures of prognosis and staging include combinations of HIV RNA level and 
CD4 cell count. (Vlahov, 1998; Cozzi-Lepri, 1998, CDC, 2001). The use of a 
combination of prognostic indices can enhance the accuracy of the prediction.
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1.6 Gender effect
For some years there has been debate over a potential gender effect on the 
natural history of HIV and patient outcome, especially after starting antiretroviral 
therapy. However, although in the majority of cases gender has not been found to 
be associated with outcome (Nicastri, 2005; Mocroft, 2003), in the pre-HAART era 
some studies suggested possible advantages for male patients (Lundreg, 1994; 
Reeves, 1998; Farzadedgan, 1998; Anastos, 2000), though others suggested that 
women might do better (Prins, 1999; Buira, 1992;Junghans, 1999; Evans, 1997).
The impact of gender on the manifestations and progression of HIV disease is still 
being investigated. Initially, it appeared that women progressed more rapidly than 
men, presenting with a different spectrum of opportunistic conditions. However, 
when controlling for the tendency of women to have reduced access to healthcare 
resulting in more advanced disease at HIV diagnosis, gender-based differences 
appeared to be less marked (Chaissson, 1995, Cozzi-Lepri, 1994). Better 
measures of viral activity, though, have once again raised the issue of the effect of 
gender on the progression of the disease. This has resulted in a renewed interest 
on the impact of gender, hormones, and demographic factors on the progression of 
HIV infection.
In general, the predictors of the rate of HIV disease progression and survival 
among women are the same as in men. CD4 cell count depletion and higher HIV 
RNA level are strong predictors of progression and survival in women. Recent 
results suggest that RNA levels can be 30% lower in women than men in the same 
CD4 cell count category. Similar results occurred in analyses restricted to people 
with a primary infection or when HIV culture was used to quantify cell-associated 
infectious units rather than RNA assays for viremia (Sterling, 1999). Generally, 
lower levels of circulating HIV RNA suggest lower steady-state levels of cell- 
associated infectious unit, and should be associated with better outcome.
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However, several recent studies suggest that the lower HIV RNA level does not 
provide benefit to women. Comparing men and women with a similar HIV viremia, 
women experienced more rapid CD4 cell depletion and faster progression to AIDS 
and death, even when race and age are taken into consideration (Farzadegan, 
1998). In vertically infected children there are distinctive differences by gender, 
which are however less marked than those by race (ECS, 2004). In most studies 
women have shorter duration of infection prior to AIDS and death than men, but 
these differences tend to disappear when CD4 cell count and drug use are taken 
into consideration ( Alioum, 1998; Santoro-Lopes, 1998).
1.7 TheHAARTEra
A significant decline in mortality has been noted in countries that are able to 
provide highly active antiretroviral therapy (HAART) (Mocroft, 2003; Palella, 1998; 
Egger, 1997; Mocroft, 2000). The death rate across Europe dropped rapidly, and 
within 2 years of the widespread availability of HAART, the number of deaths was 
less than a fifth of those before HAART. This followed the results of a multitude of 
clinical trials that demonstrated the clinical and virological benefits of HAART 
(Bartlett, 1996; Collier, 1996; Hammer, 1997).
The initial success associated with HAART might not have continued, and high 
levels of treatment failure have been reported, associated mainly with serious 
adverse events, emergence of drug resistance, difficulties in maintenance of long­
term adherence, and the few types of drugs available. Adherence to medication 
regimens, bioavailability of medications and inadequate dosing can trigger the 
emergence of antiretroviral resistance (Hirsch, 2003). In addition to drug 
resistance, clinical treatment failure is also associated with the rapidity of 
progression of the disease. The introduction and continued use of HAART over 
the past six years has resulted in very low morbidity and mortality rates across 
Europe, suggesting that limitations of current treatment, including potential adverse
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effects of long-term HAART and problems with compliance, have not yet affected 
the clinical success of HAART in the population (Mocroft, 2003).
The continued fall in morbidity and mortality in the late-HAART treatment era could 
relate to increased experience of treatment with HAART, better understanding and 
management of complicated drug regimens and toxicities, and of the role of drug 
resistance. Additionally, the availability of new drugs such as efavirenz, abacavir, 
and kaletra, and use of HAART without previous antiretroviral treatment (i.e., 
treatment naive), or with antiretrovirals not previously given, might all have 
contributed to improved long-term adherence and subsequent survival.
Nonetheless, clinical progression continues to occur among recipients of HAART, 
particularly among persons who received antiretroviral treatment before initiation of 
HAART (Ledergerber, 1999), which is associated with drug resistance.
The reductions in morbidity and gains in survival in HIV patients that have been 
demonstrated in many developed countries do not extend to developing countries 
in which the majority of HIV cases worldwide occur. It is in resource-poor countries 
where efforts still need to be made to make antiretroviral therapy widely available 
and to provide continuity of care and resources for assessment of drug efficacy and 
tolerance.
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1.8 Key points
• Health related lifestyle changes and use of antibiotics for the cure of sexually 
transmitted disease have changed the perception of sexual risk over the last 
century, decreasing the risk of adverse pregnancy outcome.
• It was in the 1970s that wider dissemination of HIV occurred with the first cases 
of AIDS appearing in the 1980s.
• Nearly 37 million people world-wide are estimated to living with HIV infected 
with HIV, of whom about 17.6 million are women; out of 610 thousand people 
living in Central and Western Europe, 160 thousand are women.
• Globally, there are currently two HIV-infected women for every three infected 
men but it is expected that the number of new infections among women will 
equal those among men shortly.
• Women who become pregnant, are now most likely heterosexually infected and 
older than was previously the case.
• Changes in the therapeutic management of HIV disease has resulted in a 
significant improvement in AIDS-free survival, with increasing numbers of 
women becoming pregnant while on combination therapy.
• Cell death in a variety of human cell lines results from HIV infection and a large 
number of laboratory tests have been evaluated as prognostic indicators in HIV 
infection.
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Chapter 2 Women and HIV infection: reproductive health,
childbearing choices and outcome
“Life is a fatal sexually transmitted disease!”
Source: Prof RV Short, Dept Of Obstetrics and Gynaecology, Prof Of 
Zoology; “Reproduction in Mammals, Fertility, AIDS and HIV”
Royal Women’s Hospital, Monash University of Melbourne, 1997.
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2.1 Introduction
Good standards of reproductive health enable women to practise and enjoy sexual 
relationships in safety, to regulate their own fertility, reproduce safely and to bring 
pregnancies to a successful outcome REFS. In order for this to occur, women 
require a health infrastructure that enables access to safe contraceptives, 
obstetrical, ante-natal and post-natal care, abortion, and appropriate services to 
prevent and treat diseases of the reproductive system. HIV-infected women have 
special needs in sexual and reproductive health, including information and services 
to protect their own health as well as to reduce the risk of mother-to-child HIV 
transmission.
Reproductive counselling to individuals with HIV might motivate them to ask for 
reproductive care in order to limit the risk of infection for their partners, to limit the 
risk of toxicity for the fetus and to reduce the vertical transmission rate. The best 
way to avoid perinatal transmission of HIV is the protection of women from 
infection.
2.2 HIV and Reproduction
Results from studies in Africa, as well as in developed countries, have suggested 
that HIV may have an adverse effect on fertility in both HIV symptomatic and 
asymptomatic women (Gregson, 1999; Blair, 2004; Degrees, 1997). However, 
some European reports suggest that the incidence of pregnancy decreased with 
HIV progression but that pregnancies after HIV diagnosis appear to be related 
largely to social and cultural attitudes (van Benthem, 2000). In a cross-sectional 
study in Uganda, the likelihood of a recognized pregnancy was lower in HIV- 
infected women than in HIV-uninfected women and lowest in women who were 
symptomatic from HIV or were coinfected with syphilis (Gray, 1998) A prospective 
study in South Africa found that pregnancy rates were 12% lower in HIV infected
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women and that HIV could only explain a small part of the fertility decline (Camlin, 
2004).
On the other hand, in a US prospective cohort study, women with HIV were more 
likely to conceive than at-risk uninfected women, but pregnancy outcomes were 
similar (Massad, 2004). With the widespread use of HAART there are anecdotal 
reports of HIV-infected women living in Europe more likely to want to become 
pregnant (Watts, 2004). The potential increase in pregnancy rates during the era 
of widespread use of highly active antiretroviral therapy highlights the need for 
prevention treatment (Blair, 2004). HAART can be very effective in terms of 
prolonged life and quality of life, but it may also have effects on fertility and 
fecundability. The use of combination therapy can affect the desire for parenthood, 
either impacting on the biological ability and/or on the personal desire of maternity. 
In the HIV-infected population, as in the general population, there are a number of 
other factors that have an impact of the desire of maternity, for example parity or 
ethnicity. In a recent report, pregnancy rates were compared before and after HIV 
diagnosis by geographical origin (sub-Saharan Africa versus European) among 
533 HIV-infected women in France (Forquet, 2001). Among women of African 
origin, pregnancy incidence and birth rates increased after HIV diagnosis, in 
women with less than two live births at diagnosis. Among women of European 
origin, the incidence of pregnancy and terminations after HIV diagnosis were three 
times lower than in women of African origin. These results suggest that fertility 
plans reflect culture rather than knowledge of HIV diagnosis.
Most studies to date examining the impact of pregnancy on HIV disease have been 
small but have not shown significant differences in HIV progression or survival 
between pregnant women and non-pregnant women with HIV infection (Brettle, 
1995; French, 1998). A meta-analysis of seven prospective cohort studies found 
no overall significant differences in death, HIV disease progression, progression to
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an AIDS-defining illness, or fall in CD4 count to below 200/mm3 between cases and 
controls (French 1998). Repeat pregnancies do not appear to have a significant 
effect on the course of HIV disease (Minkoff, 2003). Overall progression rates of 
HIV disease are similar in men and women, suggesting indirectly a limited effect of 
pregnancy on HIV progression.
2.3 HIV and gynaecological problems
HIV-infected women commonly suffer from gynaecological problems but insufficient 
data have been collected and analyzed in order to establish whether they are 
significantly different from the general population. It has been reported that women 
infected with the human immunodeficiency virus are significantly more likely to 
have prevalent and incident gynecologic disorders but not disorders related to risk 
taking (sexually transmitted diseases). The latter disorders increased in women 
with CD4(+) cell counts >500 cells/mm3 (Minkoff, 1999). It has also been reported 
that only 9% of 67 women were admitted to an inpatient AIDS service with a 
primary gynaecological problem, but 83% had coexisting gynaecological disease 
when evaluated (Frankel, 1997).
Although there have been few epidemiological observations on gynaecological 
problems in HIV-infected women, we can assume that certain symptoms can be 
directly related to HIV disease, others to HIV drug treatment and others still can be 
specifically related to the woman -  irrespective of her HIV status. We can expect 
that some sexually transmitted infections may be more present in this group of 
women who acquired HIV in a heterosexual context (Lurie 2003).
HPV infection and cervical dysplasia are more common in HIV-1-infected women 
than in other women (Duerr, 2000; Palesky, 1999; Cu-Uvin, 1999; Massad, 2001). 
Concomitant genital infections are common in HIV-1-infected women, and their 
effects on the natural history of HPV infection have not been well studied. Bacterial
39
vaginosis were present in 42% of HIV-1 infected women at the time of enrollment 
into the Women's Interagency HIV Study (Greenblatt, 1999), and appear to be 
more persistent in HIV-1 infected women than in other women (Jamieson, 2001). 
Given the higher prevalence of HPV infection and frequent concomitant genital 
infections in HIV-1 infected women than in other women, any potential associations 
between HPV infection and other genital infections could be accentuated, 
especially in women with severe immunosuppression (Watts, 2005)
Gynaecological problems are directly related to reproductive health because most 
of HIV-infected women are in their prime reproductive years. With the widespread 
use of antiretroviral therapy, which has a positive impact on life expectancy and 
quality of life, these problems will be ever more present. It is likely that antiretroviral 
therapies might impact on the functionality of the reproductive system -  directly 
causing menstrual irregularities or ovarian dysfunction (Clark, 2001).
2.4 Contraception
To date only condoms have been shown to reduce the risk of transmission of HIV. 
The options to avoid a pregnancy available to HIV-infected women are no different 
from those available to non-infected women, which are condoms, hormonal 
contraception, intrauterine devices and spermicides. After condoms, hormonal 
contraception is the second most commonly used contraceptive method; there is, 
however, some concern that its use may be associated with an increased risk of 
HIV acquisition.
Hormonal contraception can interact with antiretroviral medication resulting in 
either a decreased efficacy of the contraception or increased or decreased 
concentrations of the coadministered drug (CDC, 1998). Much evidence exists that 
that users of hormonal contraceptives are at increased risk of genital tract shedding 
either directly or indirectly through increasing the risk of cervical ectopy (Wang,
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2004; Mostad, 1998; Mostad, 2000). Indeed, we hypothesize that epithelial
changes secondary to the use of hormonal contraception may increase 
susceptibility and vulnerability to HIV (Mostad, 1998; Plummer 1998).
The use of intrauterine devices has been shown to increase the risk of HIV 
infection and to be associated with a series of side effects that exist amongst HIV- 
uninfected women also. These side effects include increased menstrual duration 
and foreign body inflammatory reaction, which can, on their own, play an important 
role in increasing the risk of infection with HIV. A worsening of drug-induced 
anaemia, common in women taking HIV medication, can also result from these 
side effects.
In in vitro studies, spermicides have been shown to be able to kill HIV and other 
sexually transmitted agents/pathogens such as Chlamydia and gonorrhoea. Some 
studies have evaluated if regular use of spermicide may have a protective effect on 
HIV transmission. A UNAIDS trial raised concern that spermicide might not only 
not be protective but might increase the risk of HIV transmission (Altman, 2000). 
The use of spermicide is known to result in increased genital ulcers, which may act 
as an increased risk factor for HIV transmission.
The consistent use of condoms provides the best-known protection against sexual 
transmission of HIV and should be emphasized for all HIV-infected and at-risk 
women to decrease risk of HIV transmission/acquisition and 
transmission/acquisition of other STDs. Other barrier contraceptive methods 
provide limited STD protection and have not been shown to offer significant 
protection against HIV transmission. Some authors suggest a sizeable proportion 
of women do not use any form of contraception independent of their desire to 
conceive. This could be linked to their social environment -  family pressure or less 
access to healthcare and lack of knowledge of the options available to them.
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Existing studies are still inconclusive as to whether the use of hormonal 
contraception could be a safe option for preventing pregnancies in HIV-infected 
women.
2.5 Choices regarding childbearing
Historically, the medical community has considered HIV a serious barrier to 
reproduction. In 1994 the Ethics Committee of the American Society for 
Reproductive Medicine expressed concern about potential transmission of the virus 
to an uninfected partner or to the couple’s offspring. It suggested that physicians 
counsel couples about the option of adoption, or not having children (Ethics 
Committee of the ASRM, 1994).
In relation to HIV-discordant couples however, over the past 10 years the 
introduction of potent antiretroviral therapy has resulted in HIV-infected patients 
living longer, healthier lives. Many health care providers and HIV-infected people 
now view HIV infection as a manageable chronic illness and seek to maintain 
normal lives. This would likely include a ‘normal’ desire for children.
The desire by HIV-infected women to conceive has not been a topic of research for 
a long time. Similar to the general population, HIV-affected couples desire to have 
children. Chen found that 28% to 29% of 1421 HIV-infected adults surveyed 
wanted to have children sometime in their lives (Chen, 2001). In a retrospective 
study, HIV-infected subjects cited raising children as a way to give purpose to life. 
In addition, many HIV-infected women reported pregnancy and childbirth as a way 
to regain their sense of womanhood and sexuality, often making childbearing a 
high personal priority. In view of these data, health care professionals now 
balance concerns about the risks of HIV transmission with the patients’ desire to 
have children.
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Also, interventions including antiretroviral therapy, elective caesarean section and 
refraining from breast feeding, have dramatically decreased the risk of vertical 
transmission to 2% or less (Dorenbaum, 2002; Simpson, 1997; Mandelbrot, 
2001 ;Cooper, 2002). As a consequence of these changes in the management of 
HIV infection, the CDC amended its previous recommendations in 2001, bringing to 
the forefront the importance of reproductive issues, stating that HIV-infected 
pregnant women should receive information about all reproductive options and that 
reproductive counselling should be nondirective and supportive of the patient’s 
decision (CDC, 2001).
Medical and social conditions of couples infected with HIV vary widely. A 
serodiscordant couple is defined as one HIV-infected and one HIV-uninfected 
partner. A seroconcordant couple is defined by two HIV-infected partners. 
Serodiscordant couples face many obstacles to considering reproduction, 
specifically the risk of HIV transmission between partners and transmission to the 
child. Men and women are each at risk of transmission from their HIV-infected 
partners. Studies indicate that although the risk of heterosexual transmission is 
relatively low, rate of male-to-female transmission per contact is significantly 
greater (0.001) than the risk of female-to-male transmission (<0.001). These 
probabilities increase with higher plasma HIV-1 RNA levels in the HIV-infected 
partner and the presence of other sexually transmitted diseases in either partner. 
A meta-analysis conducted by Davis and Weller in 1999 reported 0.9 
seroconversions per 100 person-years of observation among participants who 
reported always using condoms, compared with a seroconversion rate of 6.7 per 
100 person-years of observation among those who reported never using condoms. 
This analysis suggests that consistent use of condoms provides an 85% reduction 
in HIV transmission risk, compared with no use of condoms (Davis, 1999). Eighty 
percent of HIV affected couples surveyed that had previously conceived had
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engaged in unprotected intercourse to achieve pregnancy. Despite transmission 
risks with unprotected sexual intercourse, HIV-discordant couples are often willing 
to practice unsafe sexual intercourse in order to conceive (Mandelbrot, 1997). 
Cusick and Rhodes found that HIV-affected couples associated condom use with 
the “early stages” of a relationship, and that encouraging continued safer sex 
seemed to threaten love and intimacy as the relationship matured (Rhodes, 2002). 
Reports from interviews with 60 people with HIV and 40 of their caregivers 
suggested that HIV-infected individuals thought seeking a seroconcordant partner 
was an acceptable alternative to celibacy However, the threat of horizontal and 
vertical transmission of a drug-resistant strain of HIV still necessitates safe sex.
Some research suggests that the use of assisted reproductive techniques 
decreases the chance of sexual transmission to almost negligible rates, and thus 
provides HIV-infected couples with the possibility of a pregnancy while minimizing 
the number of “unprotected” exposures necessary to conceive. Serodiscordant 
couples in which the woman is HIV-infected have significant concerns about HIV 
transmission to the child and transmission to the HIV-uninfected man. Artificial 
insemination and self-insemination can be used to decrease the risk of HIV 
transmission to the male partner. Autoinsemination is available to HIV-infected 
women as they can inseminate themselves with freshly ejaculated semen using a 
syringe (without the needle) or a disposable pipette.
Reproductive options are available to serodiscordant and seroconcordant couples 
and there is anecdotal evidence to suggest that HIV-infected women may now 
positively choose to become pregnant and that those who do become pregnant are 
less likely to have this pregnancy terminated, because their own disease is well 
managed and interventions to reduce the risk of vertical transmission are available.
44
2.6 HIV and Pregnancy
Pregnancy involves genetically disparate individuals and, in the context of HIV 
infection, the coexistence of an uninfected fetus in an infected mother. 
Furthermore, these two different individuals have different pharmacokinetic 
characteristics. Therefore, a pregnant woman infected with HIV cannot be simply 
considered an infected adult when planning her antiviral treatment.
The issue of antiretroviral treatment during the nine months of pregnancy should be 
put in the context of the long-term progression of HIV infection, in order to balance 
the maternal benefits with the exposure of the fetus to potentially toxic drugs for its 
entire prenatal life. As well as the risks and benefits for the mother and for the 
child, pharmacological treatment during pregnancy needs to be adjusted to the 
physiological modifications that take place in the pregnant woman. Many 
parameters influencing drug pharmacokinetics are modified during gestation, 
starting from the first weeks of amenorrhoea. There is a change in salivary pH, 
delayed gastric emptying and reduced bowel transit, marked increase of plasmatic 
mass and kidney filtration rate, decreased albumin and increased globulin 
concentrations. Both the trophoblast and fetal liver can metabolise drugs and 
amniotic fluid can also become a significant drug reservoir. The pharmacokinetic 
of drugs that have a short half-life, a narrow therapeutic window or are highly 
liposoluble (thus easily crossing the placental layers) can be significantly changed 
during pregnancy.
During pregnancy, cell-mediated immunity is reduced, with an accompanying 
decline in the T-cell helper-suppresser ratio. On the basis of case reports of 
women dying of AIDS in pregnancy or shortly after delivery and of the 
immunosuppressive effect of HIV, it was initially hypothesized that pregnancy in 
HIV-infected women could lead to an accelerated decline in CD4 cell count and to 
progression of disease.
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However, prospective studies have found no convincing evidence that pregnancy 
accelerates the progression of HIV disease, while natural history studies have 
found gender effect for progression or overall survival, but not providing any 
evidence for the existence of a pregnancy effect on disease. Other studies have 
reported stable levels of HIV activity during pregnancy, in terms of viral load and 
CD4 cell percentage.
In both HIV-positive and HIV-negative women there is a decline in absolute CD4 
cell counts in pregnancy, which is thought secondary to hemodilution; which is in 
line with the finding that the percentage of CD4 cells remains relatively stable. 
(European Collaborative Study, 1997; Miotti, 1992). When comparing changes in 
CD4 count/percentage over time, there is no difference between HIV-infected 
pregnant and non pregnant women (Tuomala, 1997), suggesting that pregnancy 
does not accelerate decline in CD4 cells. Adverse pregnancy outcomes may occur 
secondary to underlying disease processes (or their treatment), as well as for 
unknown reasons. Recent data suggest that HIV, especially when more advanced, 
may result in increases in certain pregnancy complications. Furthermore, concerns 
have been raised that antiretroviral treatment itself may increase some adverse 
outcomes in pregnancy (Brocklehurst, 1998).
2.7 Mother to child transmission
Mother-to-child, or vertical, transmission of HIV-1 can occur during pregnancy, 
around the time of delivery or postnatally, through breastfeeding. Without 
prophylactic interventions, including avoidance of breastfeeding, vertical 
transmission rates range from 15-40% (Working group on mother to child 
transmission 1995, ECS 1996). Maternal plasma HIV RNA level is the best 
individual predictor of MTCT risk, and other factors increasing risk include AIDS, 
primary infection, vaginal delivery, low CD4 count, and prematurity (Kuhn, 1999; 
European Collaborative Study, 1999; Mandelbrot, 1996; International Perinatal HIV
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Group, 2001,Newell 1998,Thorne 2004). Breastfeeding is associated with an 
approximate doubling of overall MTCT risk, with the risk remaining as long as 
breastfeeding continues.(Nduati 2000).
In Western Europe where interventions to reduce mother to child transmission are 
nowadays available, including antiretroviral prophylaxis, elective caesarean section 
and refraining from breastfeeding, the risk of transmission of HIV from the mother 
to the fetus can be substantially reduced to less than 2% (Dorenbaum, 2002; 
Simpson 1997; Mandelbrot, 2001; Cooper, 2002). Table 2.1 illustrates the use of 
interventions for prevention of mother to child transmission in Europe since the 
beginning of the epidemic.
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Table 2.1 Interventions for the prevention of vertical transmission in 
Europe (Thorne 2005)
Pre-1994
1994
1994-1996
1997
1999
2002
2002-2005
No antiretroviral prophylaxis available for PMTCT
MTCT rates in Europe around 15-18% (Gabiano 1992, ECS ...)
Results of the ACTG 076 placebo-controlled clinical trial (Connor 
1994)
- three-part regimen of zidovudine monotherapy
- antenatal oral zidovudine started at between 14 and 34 weeks 
gestation
intravenous zidovudine during labour
neonatal oral zidovudine for 6 weeks after delivery
MTCT rate of 8.3% in the intervention arm versus 25.5% in
the placebo arm at 18 months (no breastfeeding)
Observational evidence for protective effect of elective caesarean 
section in MTCT (ECS 1994)
Rapid uptake of zidovudine monotherapy for PMTCT (Mayaux
1997) and elective caesarean section (ECS 1998)
HAART becomes the standard of care for adults requiring 
treatment, although at this time had only limited use in pregnancy 
in Europe
Results of the mode of delivery randomised trial (The European 
Mode of Delivery Collaboration 1999) and meta-analysis (The 
International Perinatal HIV group. 1999)
- elective CS before labour and before rupture of membranes is 
associated with a two-thirds reduction in MTCT risk
Results of the PACTG 316 placebo-controlled trial (Dorenbaum A 
2002)
Single dose nevirapine intrapartum and to infant versus 
placebo in addition to non-study ART (antenatal and neonatal) 
MTCT rate of 1.4% in nevirapine arm versus 1.6% in placebo 
arm
- single dose nevirapine did not confer an additional protective 
effect in this population
European consensus guidelines on pregnancy and HIV infection 
updated (Newell 2002)
MTCT rates of less than 2% in non-breastfeeding populations 
(ECS 2005)
Antenatal HAART use widespread in Europe (ECS 2005)
48
It has been suggested that exposure to antiretroviral therapy in utero or early life 
could have an adverse effect on the infant in the medium- to long-term, but, 
although this effect is poorly quantified, it is likely to be relatively rare.
Since the mid 1990s, potent and effective antiretroviral therapy (HAART) to delay 
progression of disease in HIV-infected adults has become the standard of care. 
Such regimens are now usually applied before serious disease has developed, and 
an increasing number of HIV-infected adults are receiving complex antiretroviral 
regimens. There is a lack of information on the impact of antiretroviral therapy 
before, during and after pregnancy or the impact of caesarean section delivery on 
disease progression of HIV-infected women. The management of pregnancy in 
HIV-infected women, which allows for the optimum care of both woman and child, 
is becoming increasingly complicated.
Knowledge about timing and risk factors has determined approaches to 
interventions to reduce the risk of vertical transmission (Table 2.2). Based on 
indirect evidence it is now generally accepted that, in the absence of breastfeeding, 
about 75% of vertically infected infants acquire their infection around the time of 
delivery, while in breastfeeding populations this is about 50% (Rouzioux, 1995). Risk 
factors for vertical transmission include indicators of progression of maternal disease, 
such as viral load and clinical disease, and obstetrical and neonatal factors such as 
prematurity, mode of delivery and breastfeeding. Prophylactic antiretroviral therapy 
aims to reduce the viral load in the mother, which remains the stronger predictor of 
perinatal transmission, and thus prevent transmission. Elective caesarean section 
delivery avoids contact of the foetus with contaminated maternal secretions, 
microtransfusions between maternal ad fetal compartment and avoids possible 
transmission through ascending infections after rupture of membranes. Refraining 
from breastfeeding reduces exposure to potentially infectious milk. Approaches to 
reduce postnatal transmission in settings where bottle feeding is unacceptable
49
include early weaning and exclusive breastfeeding as well as antiretrovirals for 
brestfeeding mothers.
Table 2.2 MTCT risk factors in the HAART era based on 4500 mother-child pairs 
(Source: European Collaborative Study 2004)
Unadjusted Odds Ratio Adjusted OR (95% Cl) 
n=1200
Viral load:
<1000 copies/ml 1.00 1.00
>10,000 2.30 2.20 (1.19-4.07)
ART:
None 1.00 1.00
Mono/dual 0.29 0.37 (0.18-0.78)
HAART 0.09 0.11 (0.03-0.40)
MoD:
Vaginal 1.00 1.00
Emergency CS 0.48 0.53 (0.23-1.26)
Elective CS 0.24 0.18(0.08-0.38)
Gestation:
Term
Premature
1.00
1.25
1.00
2.09 (1.18-3.69)
*multivariable analyses adjusting for RNA VL, ART, mode of delivery and
gestational age at delivery
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2.8 Prophylactic anti-retroviral therapy
After the positive results from the American-French trial ACTG076 (Connor 1994), 
which showed that zidovudine administered antenatally, during labour and 
neonatally reduced vertical transmission risk by over two-thirds in a non­
breastfeeding population, trials were set up to investigate shorter, easier and 
cheaper zidovudine regimens to be effective in both breastfeeding and non­
breastfeeding populations. Results from these trials confirm the substantial effect 
of zidovudine in reducing the risk of vertical transmission (Shaffer 1999; Guay 
1999; Wade 1998). A recent issue is the fact that increasing numbers of HIV- 
infected women are becoming pregnant while on combination therapy for their own 
disease progression (Figure 2.1). Observational studies have confirmed a 
substantial reduction in vertical transmission risk associated with the combination 
regimens, emphasising in this case the dual nature of vertical transmission 
prophylaxis and optimal treatment of the mother’s HIV infection.
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HIV-infected women may worry about the effects that antiretroviral drugs will have 
on the pregnancy and the child. Pregnancy requires unique considerations, 
including the possible need to alter dosage as a result of physiologic changes 
associated with pregnancy and the potential for adverse short or long-term effects 
on the fetus and newborn. No studies have indicated that there is an increase in 
birth defects related to HIV infection; however, efavirenz is not recommended in the 
early stages of pregnancy REF. Birth defects (anencephaly, anopthalmia, or cleft 
palate) occurred in 15% of monkeys born after efavirenz exposure during the first 
trimester of pregnancy. According to the Antiretroviral Pregnancy Registry, the rate 
of birth defects among infants born to 400 women exposed to zidovudine or 
lamivudine during the first trimester has been no higher than the rates among 
infants who were exposed after the first trimester (Antiretroviral Pregnancy 
Registry, 2004) Additionally, there are no well-controlled studies of teratogenicity 
using nevirapine, therefore it should be used with caution and in accordance with 
its label. There may also be enhancement of metabolic side effects, such as 
mitochondrial toxic effects leading to increased lactic acidosis in pregnant women 
on nucleoside reverse transcriptase inhibitors.
Of concern are the recent reports of a small number of serious adverse effects 
possibly associated with exposure to antiretroviral therapy in the form of 
mitochondrial dysfunction both in women and children (Blanche, 1999; Lorenzi,
1998).
High rates of adverse pregnancy outcome have been described (preterm delivery, 
low birth weight and intrauterine growth restriction) and risk factors for these 
adverse outcomes, compared to those of uninfected women of similar 
race/ethnicity who received adequate prenatal care. Adverse pregnancy outcomes 
have been associated with HIV disease stage, but in most of these studies, only a 
small percentage of women were receiving ART (Lambert, 2000). HIV-associated
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risk factors may become less or more important in women receiving ART. In a 
recent analysis of European data it was shown that HIV-infected pregnant women 
treated with two or more anti-retroviral drugs are at a nearly three-fold increased 
risk of premature delivery compared to those on no or monotherapy (European 
Collaborative Study 2000). This association was especially pronounced when 
treatment included protease-inhibitors (PI) and when started before or in early 
pregnancy.
An increased rate of prematurity (<37 weeks) associated with use of PI was first 
reported in a report in 1998 from a Swiss study, of 30 Pl-exposed infants, which 
also reported two cases of intracerebral haemorrhage and extrahepatic biliary 
atresia. The rate of prematurity in these 30 infants was significantly higher than 
that among infants exposed to zidovudine (33% versus 17%).
Data from two cohort studies were merged, the European Collaborative Study and 
the Swiss Mother+Child HIV Cohort Study, involving nearly 4000 mother-child 
pairs, and the use of antenatal antiretroviral therapy (with a PI) was associated with 
a 2.5 times greater risk of premature delivery compared with no treatment, after 
adjustment for maternal CD4 count and use of illicit drugs. A dose-response 
relationship was suggested by the finding that risk of premature delivery was 
greatest for those women who started HAART before pregnancy or during the first 
trimester of pregnancy.
Prematurity has not been identified as an adverse effect of antiretroviral therapy in 
pregnancy by several large studies, including a meta-analysis of over 3000 mother- 
child pairs enrolled in observational studies in the USA (The Perinatal Safety 
Review Working Group, 2000). An immunological mechanism may be behind the 
association between shorter duration of pregnancy and exposure to HAART (see 
Chapter 3).
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2.9 Mode of delivery
A consistent body of evidence from observational studies (Dominguez, 2003; 
Rowland, 2001), a meta-analysis (The International Perinatal HIV Group, 1999) 
and a randomized trial (The European Mode of Delivery Collaboration, 1999) 
indicate that elective caesarean section before onset of labour and rupture of 
membranes significantly reduces the risk of transmission compared to both vaginal 
and emergency caesarean section deliveries.
Caesarean section avoids the passage of the fetus in the birth canal where HIV, 
present in cervical secretions, can infect the fetal ocular and buccal mucosas. 
When the procedure is performed before labour, it can also impede the passage of 
maternal blood in the fetal circulation through placental breaks occurring with 
contractions. According to these two possible ways of protection against HIV 
infection, caesareans can be divided into those performed prior to labour, which 
can interfere with both the bloodborne and the transmucosal routes of infection, 
and procedures carried out during labour when only the latter mechanism of fetal 
contamination can be avoided.
In the European mode of delivery trial a total of 436 women were randomized to 
either vaginal or caesarean section delivery. The trial results confirm findings from 
earlier observational studies that vaginal delivery is associated with a more than 
two-fold increased risk of vertical transmission of HIV infection, independent of the 
use of prophylactic antiretroviral therapy. The transmission rate in the trial was 
1.8% in women allocated to caesarean section compared with 10.5% in those 
randomized to vaginal delivery.
It has been reported that the risk of post-partum complications in HIV-infected 
women may be higher than in uninfected women, especially after caesarean 
section (Semprini, 1995, Marcollet, 2002; Rodriguez 2001). In the light of the low
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risk of vertical transmission associated with the use of antiretroviral therapy, the 
assessment of the risk of post-partum morbidity associated with elective caesarean 
section or vaginal delivery has gained in importance. It has recently been 
suggested that in women successfully treated with highly active antiretroviral 
therapy with a low (<1000 copies/ml) or undetectable viral load near the time of 
delivery the potential side effects of caesarean section delivery may no longer 
outweigh the benefits of reduced vertical transmission risk (ECS 1999; loannidis, 
2001).
With increasing numbers of pregnant HIV-infected women receiving antiretroviral 
prophylaxis and having an elective caesarean section delivery, more information 
has become available on the interaction between these interventions. In the 
French Perinatal Cohort Study, multivariate analysis of 902 mother-child pairs 
receiving zidovudine prophylaxis indicated a five-fold reduction in transmission risk 
following elective caesarean section compared with vaginal delivery, with a vertical 
transmission rate in women exposed to both interventions of 0.8%. Similarly, the 
Swiss Neonatal HIV Study Group reported a 0% transmission rate in 31 infants 
born to women receiving both interventions, compared with 8% after elective 
caesarean section without zidovudine (7/86), 17% (4/24) after zidovudine alone 
and 20% (55/271) after no intervention.
2.10 Policy and practice
Although prevention of mother-to-child transmission of HIV is a success in 
developed country settings, with vertical transmission rates of less than 2% 
reported, programmes need a coherent approach to include the identification and 
monitoring of infected women from before pregnancy, as well as antenatal and 
post-natal management. As many European centres only see a few pregnant- 
infected women annually, and given the rapidly changing field of HIV therapy, 
consensus expert guidelines are important in guiding practice at a local level. The
56
European consensus on the management of pregnancy and HIV infection, 
stressed the need not only to offer, but also to recommend, antenatal HIV testing 
as an integral component of antenatal care (European Collaborative Study, 2003). 
The first step to effective prevention of mother-to-child transmission is identification 
of infected women.
Management of pregnant HIV-infected women, or those wishing to become 
pregnant, is predominantly multidisciplinary in approach. This allows for sharing of 
expertise so that the woman receives optimum care, regarding her own HIV 
disease, reducing vertical transmission risk and the pregnancy and delivery per se.
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2.11 Key points
• Reproductive counselling to individuals infected with HIV might motivate them 
to ask for reproductive care.
• HIV may adverse affect fertility outcome but it does not appear to impact on 
HIV disease.
• The use of HAART is associated with an increase in pregnancy rates in HIV 
infected women as it may affect the desire of maternity due to its effectiveness 
in prolonging life and improving quality of life.
• ART may affect fertility and fecundability (biologic ability to become pregnant).
• Gynaecological problems are related to reproductive health because HIV- 
infected women are mostly in their reproductive years.
• Contraceptive options available to HIV-infected women are no different from 
those available to non-infected women.
• Desire to conceive in the HIV population is an important topic of research.
• In Western Europe where interventions are available the risk of vertical 
transmission is today less than two percent.
• There are reports of adverse events associated with exposure to ART, in 
particular premature delivery in women treated with HAART.
• Elective caesarean section significantly reduces the risk of mother to child 
transmission, but the risk of post partum complications needs evaluation in the 
HAART era.
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Chapter 3 Immunological aspects of pregnancy in HIV-infected 
women
During a norm al pregnancy there is an increase in the production o f Type 2  
cytokines, accom panied by a decrease in the production of Type 1 cytokines, 
resulting in a Type 1 to Type 2  shift. Indeed, it has been suggested that the 
absence o f Type 2  cytokines m ay adversely affect pregnancy outcomes with an  
increased risk for example o f spontaneous abortions. H A A R T  induces a shift 
towards a T yp e l environment and therefore, it is predictable that it affects this 
balance.
W hy were you not rejected by your mother?
Source: D r Gil M ore Reproductive Immunology, Yale University
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Immunology of pregnancy: the Th1/Th2 paradigm
A key development in our understanding of immune responses has been the 
description of the T helper 1/T helper 2 paradigm (Th1/Th2) which helps explain 
how the immune system directs responses to different types of pathogens and 
stimuli. The two major subsets of CD4 T helper cells, Th1 and Th2, have different 
patterns of cytokine production and different roles in immune responses. Each 
subset induces functions that are effective at handling certain types of pathogens, 
but can be ineffective, or even pathological if made in response to other types of 
pathogens (Mosmann, 1996, Coffman, 1999) (Figure 3.1). Th1 cells secrete IFN 
(interferon), TNF (Tumor-necrosis factor), and IL-2 (Interleukine 2). Some of these 
cytokines like TNFhave cytolytic effects contributing to cellular immunity and are 
generally considered to be Th1 -like or Th1-associated cytokines (Yui J 1994). Th1- 
type cytokines activate macrophages and cell-mediated reactions important in 
resistance to infection with intracellular pathogens, and in cytotoxic and delayed- 
type hypersensitivity (DTH) reactions (Figure 3.2).
Th2 cells secrete IL-4, IL-5, IL-6, IL-10 and IL-13; Th2-type cytokines encourage 
vigorous antibody production and are, therefore, commonly found in association 
with strong antibody responses that are important in combating infections with 
extracellular organisms. Th1 and Th2 cells are mutually inhibitory; IL-10, a product 
of Th2 cells, inhibits the development of Th1 cells by acting on antigen-presenting 
cells, whereas IFN, a product of Th1 cells, prevents the activation of Th2 cells. The 
CD4 Th-mediated response is certainly more than just Th1 and Th2, but these 
represent two extremely polarized forms that play important roles in immune 
responses.
Other cytokine patterns also exist; Th3 cells are TGF(transforming growth factor) - 
secreting CD4 cells that do not secrete IL-2, IFN , IL-4 or IL-10 and appear to be a
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unique T cell subset that includes the mucosal T helper function and the down- 
regulation of Th1 and other immune cells. Since several cell types besides T 
helper cells contribute to an overall Th1 or Th2 cytokine pattern, it has been 
suggested that these responses should instead be described as type 1 or type 2. 
Which type of reactivity, type 1 or type 2, is activated first may influence the 
subsequent outcome; if a particular T cell subset is activated first or preferentially in 
a response, it can suppress the development of the other subset. The overall 
effect is that certain responses are dominated by either humoral (type 2) or cell- 
mediated (type 1) immunity.
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Figure 3.1: Humoral and cellular response (Source: Trabattoni & Clerici 2003)
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IL-2 
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IFN- y 
IL-15
D D .I /J J j - j
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Trabattoni & Clerici, Immunology Department, University of Milan - http://users.unimi.it/~vial/
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Figure 3.2: Cellular immune responses mediated by cytotoxic T lymphocytes (CTL) (Source: Trabattoni & Clerici 2003)
M A T U R E  C Y T O T O X IC  T C E L L
TNF-oc
A g /M H C  c la s s  I
VIR A LLY IN FEC TED  or A LLO  TA R G E T C ELL
VIR A LLY IN FEC TED  or A LLO  C ELL
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3.1 Maternal immune status during pregnancy
A successful pregnancy is dependent on the ability of the maternal immune system 
to retain the fetus, which immunologically is an allograft, due to the possession of 
paternal transplantation antigen (Piccinini, 1996). The feto-placental unit produces 
Th-2 cytokines throughout pregnancy; these inhibit maternal Th-1 activity, which in 
turn protects the pregnancy (Wegmann, 1993, Marzi, 1996). Maternal generation of 
IL-2, and TNF-p is directly associated with compromise of the pregnancy. IL-2 
promotes proliferation of large granular lymphocytes in the uterus, creating 
lymphokine-activated killer cells with enhanced cytotoxic activity. In vitro IL-2 
increases the lymphocyte ability to kill cultured trophoblast cells. This would 
compromise the invasiveness of the trophoblast during implantation and placental 
growth (Reinhard, 1998, Raghupathy, 1997). While there is rather less information 
available in relation to human pregnancy, it has been shown there is an increased 
production of the regulatory cytokines like IL-10 (Th2) (Chaouat, 1999, Chaouat, 
1995).
Experiments on mice and clinical evidence in humans indicate that humoral 
responses (Th2, type 2) are potentiated during pregnancy, but that DTH, natural 
killer (NK) activity, responses to intracellular infections (Th1, type 1) and the course 
of cell mediated autoimmune disorders are ameliorated (Russell, 1997). These 
observations are consistent with a dampening of type 1 reactivity and
augmentation of type 2 immunity during pregnancy. Pregnancy seems to shift 
towards type 2. Dudley showed that cytokine responses by activated lymphocytes 
from pregnant mice are marked by a progressive decline in IL-2 (Th1) production 
and a concomitant increase in the levels of IL-4 and IL-6 (Th2) (Dudley, 1993). In
humans there are reports of significantly higher IL-10 (Th2) production by mitogen-
activated PBMC in pregnant women as compared with non-pregnant women 
(Hanna, 2000). Using a sensitive on-line quantitative RTPCR (Reverse
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transcription polymerase chain reaction) Kruse reported a significantly reduced IL-2 
and IFN (Th1) mRNA expression during normal human pregnancy (Kruse, 2000). 
Type 1/type 2 ratios revealed a shift to a pronounced type 2 status. Using flow 
cytometric techniques on a single cell level significantly increased IL-4 (Th2)- 
producing CD4 and CD8 T cells were demonstrated in normal pregnant women as 
compared to non-pregnant women. In contrast, IFN - and IL-2-producing CD4 and 
CD8 T cells were significantly reduced in pregnancy, which is suggestive of a type 
2 shift in pregnancy (Ragupathy, 1997). The Th-2 and T regulatory cytokines have 
additional critical functions in stimulating cell growth and differentiation. Thus there 
is a fine balance of cytokine production between mother, placenta, and the fetus, 
orchestrating a down-regulation of maternal immune responses to feto-paternal 
antigens, at the same time as encouraging normal fetal growth and immunological 
responsiveness.
3.2 Cytokines and pregnancy failure
The activation of some forms of maternal cellular immunity is potentially hazardous 
for fetal development. Indeed, pregnancy is not nearly as successful as one might 
think; the actual rate of early pregnancy loss after implantation may be as high as 
31% (Hill, 1992). Spontaneous abortion, defined as a clinically detectable 
pregnancy loss prior to 20 weeks of gestation, is one of the most common 
complications of pregnancy with approximately one in every four pregnant women 
undergoing one or more pregnancy losses (Clark, 1999). About 40-60%  of 
recurrent spontaneous abortions (RSA), defined as the occurrence of three or more 
pregnancy losses before the 20th week of gestation, are attributable to the so- 
called ‘known’ causes such as chromosomal anomalies, endocrinologic 
abnormalities, infections, anatomic problems and humoral factors, with as much as 
60% relegated to ‘unknown’ or ‘unexplained’ etiology (Prigoshin, 2004).
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The existence of such a large proportion of cases with unidentified etiologies has in 
part fuelled interest in the investigation of possible immunologic etiologies of 
pregnancy failure. Cellular immunity mediated by effector cells and/or their 
cytokines has been shown to have significant deleterious effects on the conceptus 
(Makhseed, 1999, Raghupathy, 2000). TNF, IFN and IL-2 (Th1) figure prominently 
among cytokines that are particularly detrimental to the survival of the conceptus. 
The administration of TNF, IFN and IL-2 into pregnant mice causes abortions while 
anti-TNF antibodies have been shown to reduce resorption rates in a murine model 
of natural, immunologically mediated abortion (Tangri, 1993). TNF and IFN inhibit 
outgrowth of human trophoblast cells in vitro and synergistically stimulate the 
programmed death of human primary villous trophoblast cells (Haimovici, 1991, 
Hill, 1995). In vitro stimulation of maternal spleen cells with placentas of mice prone 
to immunologically-mediated spontaneous fetal resorption results in the secretion 
of high levels of TNF, IFN and IL-2; these cytokines together fit the type 1 cytokine 
profile. It was not long before this intriguing association between type 1 cytokines 
and pregnancy failure was noticed that researchers observed interesting 
connections between successful pregnancy and type 2 immunity, leading to 
Wegmann and colleagues putting forward the hypothesis that the conceptus 
protects itself by secreting type 2 cytokines which down-regulate harmful type 1 
cytokines (Wegmann, 1993).
Studies on animals have shown that the injection of type 1 cytokines results in 
abortions, thus a causal relationship has been established in animal models, while 
in human studies what we have available at present are indications of a similar 
correlation between the type of maternal immune reactivity and pregnancy 
outcome. However, studies on human pregnancy loss have not yet conclusively 
proven that type 1-reactivity can indeed be a cause of pregnancy failure. One 
study that comes closer towards a causal relationship is the one by Clerici’s group
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in which cytokine production was tested 1-2 weeks before any pathology could be 
detected (Marzi, 1996). Their study on 40 women with a normal pregnancy and 
five women with spontaneous abortions showed a decreased production of IL-4 
and IL-10 (type 2) and increased production of IFN- and IL-2 (type 1) by antigen- 
stimulated PBMC in women with spontaneous abortions. Interestingly, the PBMC 
in this study were stimulated with influenza virus and with allogenic PBMC, 
implying that the type 2 bias seen in pregnancy may be generalized to any 
antigenic stimulus.
3.3 Type 1 immunity induction during pregnancy
Genetic alterations of molecular mechanisms have been shown to be directly 
involved in the expression of IL-4 or IL-12 and deficient regulation by Th1-inhibiting 
cytokines such as IL-4 or IL-10. (Mosmann, 1996, Coffman, 1999). Is it possible, 
then, that some women have a genetically determined tendency to produce higher 
levels of certain type 1 cytokines? The predominance of a given cytokine in the 
microenvironment at the time of antigen presentation is an important factor in 
driving naive CD4 T cells toward Th1- or Th2-dominated populations. IFN and IL- 
12 promote Th1 differentiation whereas IL-4 is the dominant factor in determining 
Th2 polarization. IL-12 is produced by several cell types, particularly by 
macrophages, in response to microbial products. Thus, certain infectious 
diseases, even sub-clinical ones, may result in enhanced IL-12 production causing 
an overall shift towards type 1. IFN, synthesized by NK cells in response to IL-12 
and to viral infections, also enhances Th1 development. Authors refers to the 
conceptus as an ‘innocent bystander’ when the mother must combat an infection 
with a vigorous Th1- type proinflammatory cellular immune response (Clark, 1999). 
IL-12 may play a key Th1-inducing role in the cascade of events that provoke type 
1 bias in pregnancy. Women with a history of recurrent abortion have been shown 
to have significantly elevated levels of IL-12 compared to women with a normal
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pregnancy. IL-12 stimulates the release of IFN by decidual large granular 
lymphocytes and this effect is amplified by decidual macrophages (Marzusch, 
1997).
Hormones may also contribute to the differentiation of Th cells or in favouring the 
shifting of already differentiated Th cells from one to another cytokine profile; for 
example, relaxin, a hormone produced by the corpus luteum, favours the 
development of human Th cells producing type 1 cytokines (Piccinni, 1996). A lack 
of suppression at the maternal-fetal interface may induce a type 1 shift (Michel, 
1999). Supernatant fluids from decidual cultures were shown by Clark’s group to 
inhibit lymphocyte proliferation in subsequent in vitro assays whereas supernatants 
from cultured abortion tissue had a reduced inhibitory capacity.
3.4 Mechanisms of type 1 immunity-mediated damage
The trophoblast is resistant to killing by cytotoxic T lymphocytes, conventional NK 
cells and conventional macrophages. At the same time increased plasma and 
uterine NK activity has been linked to abortion, and increased NK activity in the 
blood has been shown to be predictive of recurrent miscarriages. While direct cell- 
mediated lysis is unlikely to cause trophoblast damage, it has been proposed that 
NK cells, like activated Th1 cells, could release cytokines deleterious to the 
trophoblast. Direct effects of type 1 cytokines may include the apoptosis of 
trophoblast cells by TNF and IFN, inhibition of secretion of the growth stimulating 
GM-CSF from the uterine epithelium and perhaps most importantly the 
upregulation of procoagulant factors (Clark, 1998; Clark 1999).
It should be pointed out that in pregnancy some type 1 cytokines are not 
necessarily bad all the time; perhaps depending on their time of expression, stage 
of gestation and relative concentrations they may serve as saviours. TNF when 
administered systemically or when induced in the placenta as part of an anti­
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parasite cellular response damages pregnancy, can also stimulate the 
programmed cell death of human trophoblasts (Krishnan, 1996; Yui, 1994) . 
However, TNF is produced by normal gestational tissues and has been proposed 
to be a pivotal factor in gestation (Hunt, 1996). We have to reconcile these 
seemingly disparate observations, keeping in mind that cytokines are pluripotent, 
their functions could depend on the relative concentrations of different cytokines, 
their activities could be mitigated by receptors and antagonists and they could have 
stage-dependent functions that may seem incongruent.
Cytokines, hormones and other molecules are likely to play critical roles in directing 
the immune reactivity towards a type 2-bias and then maintaining it in that fashion. 
The Th2-inducing effect of IL-4 predominates over other cytokines, so that if IL-4 
levels reach a necessary threshold, differentiation of the Th cells into the Th2 
phenotype occurs. Recently IL-6 has been shown to polarize naive Th cells to 
effector Th2 cells by inducing the initial production of IL-4 in CD4 T cells IL-10 is 
probably one of the most critical cytokines responsible for maintaining a type 2-bias 
once established; it interferes with antigen presentation, down-regulates cytokine 
production by Th1 cells and directly or indirectly inhibits NK responses. 
Interestingly enough, the cytotrophoblast and syncytiotrophoblast have been 
shown to produce IL-10 preferentially in a gestational age-dependent manner 
(Hanna, 2000). Evidence for a possibly crucial role for IL-10 came from the studies 
of Chaouat in which the administration of IL-10 to abortion-prone mice was shown 
to reverse the high rate of fetal resorption in these mice (Chaout, 1995). Likewise, 
Rivera and colleagues showed that the increased uterine TNF, release of nitric 
oxide and apoptosis of uterine epithelia that followed administration of LPS were all 
normalized upon injection of IL-10 (Rivera, 1998). Concurrently IL-10 attenuated 
the LPS-induced fetal death rate and growth restriction, leading these researchers
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to conclude that IL-10 produced in the placenta may play vital roles in 
counteracting deleterious inflammatory cytokines.
Progesterone has been shown to favour the development of human T cells 
producing type 2 cytokines and Piccinni proposes that progesterone may therefore 
be responsible, at least in part, for a type 1/type 2 switch at the maternal-fetal 
interface (Piccinni, 1996). Progesterone has been shown to follow another 
interesting route towards influencing the Th1/Th2 balance: in an extensive series of 
studies Szekeres-Bartho and colleagues have demonstrated that in the presence 
of progesterone, lymphocytes from pregnant females produce an 
immunomodulatory protein, the progesterone-induced blocking factor (PIBF) which 
inhibits several Th1-type responses in vitro and prevents resorptions induced by 
transfer of spleen cells with high NK activity (Szekeres-Bartho, 1990). In the 
presence of PIBF, murine splenocytes activated with mitogen produce significantly 
higher levels of IL-10 and IL-4, bringing about a Th1/Th2 shift. In pregnancy, 
priming and maturation of T cells occurs in an environment that is gradually 
progesterone-enriched (Szekeres-Bartho, 1996). This would result in T-cell 
priming, activation and differentiation in the presence of lower concentrations of IL- 
2 and IFN and higher concentrations of IL-4 and IL-10, an environment that has 
been shown to favour the development of type 2 T cells.
Progesterone and relaxin appear to be hormones with opposite functions but 
produced by the same tissue (Szekeres-Bartho, 1992). Predominance of 
progesterone at the beginning of pregnancy is needed to orientate the local 
immune response towards a type 2 pattern, with type 2 cytokines down-regulating 
a potentially harmful type 1 response and preventing premature fetal rejection. On 
the other hand, relaxin may be useful in maintaining and restoring a Th1-oriented 
response that is required for delivery (Sherwood, 1994). An inappropriate local 
imbalance in the concentration of the two hormones in favour of relaxin in early
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gestation might impair the type 2 shift. Data emerging from several laboratories 
are beginning to indicate that type 1 cytokines along with a few others are probably 
also involved in causing pregnancy complications of other kinds —  pre-eclampsia 
or preterm labour (Arosio, 2004; Madazli ,2003; El-Shazly, 2004).
3.5 Cytokines and HIV
During HIV infection a shift from Type 1 to Type 2, even if not antigen specific, 
indicates progression of HIV disease (Shearer, 1998, Clerici, 2000; Clerici, 2002) 
(Figure 3.3), and HIV therapy specifically aims to reverse this shift. It has been 
suggested that an imbalance in the Th1-type and Th2-type responses contributes 
to the immune dysregulation associated with HIV infection, and resistance to HIV 
infection and/or progression to AIDS is dependent on a Th1-->Th2 dominance In 
support of this hypothesis, it has been reported that progression to AIDS is 
characterized by loss of IL-2 and IFN-gamma production concomitant with 
increases in IL-4 and IL-10 (Vasilescu, 2003).
Biological and molecular studies of HIV-1 have demonstrated that HIV is highly 
heterogeneous. In particular, HIV primary isolates display in vitro distinct biological 
properties, amongst which the rate of viral replication (slow/low or rapid/high), and 
ability to induce a cytopathic effect (nonsyncytium-inducing or syncytium-inducing) 
differentiate diverse viral strains. The prevalence and the emergence of distinct 
phenotypic variants appear to be correlated with different stages of infection. Thus, 
the asymptomatic phase is characterized by the inability to isolate HIV in culture or 
by the presence of slowly replicating nonsyncytium-inducing (NSI) isolates. In 
contrast, highly replicating syncytium-inducing (SI) variants emerge in 50% to 60% 
of HIV-infected individuals in the progression of HIV infection; the emergence of 
these viral variants is related to rapid CD4 T-cell depletion and progression to 
AIDS. Progression of HIV infection is also associated with impairment of cell- 
mediated immunity (CMI), which has both in vivo and in vitro correlates. Thus, the
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inability to develop delayed type hypersensitivity reactions (DTH) to ubiquitous 
antigens precedes and heralds the development of opportunistic infections. 
Analogously, defective production of the CMI-inducing cytokines interleukin IL-2, 
IL-12, and gamma interferon (IFN-y) and augmented production of type 2 cytokines 
IL-4, IL-5, IL-6, and IL-IO are observed in HIV infection and have been proposed as 
an in vitro immunologic marker of progression in HIV individuals.
The introduction of different antiretroviral drugs used in combination results in the 
suppression of viral replication and a degree of immune reconstitution. Immune 
reconstitution in HAART-treated individuals is incomplete because increases in 
CD4 cell counts are usually only partial, and the HIV-specific immune response is 
only marginally ameliorated in these patients. Some authors suggest that an 
improvement in CD4 T cell counts and a reduction in HIV plasma viraemia in 
chronically HIV-infected individuals are early HAART associated events, whereas 
the modulation of antigen-specific responses and cytokine production are later 
events that occur after a prolonged period of therapy. IL-2 and IFN production is 
increased in long-term HAART treated individuals (2 years of therapy) (Figure 3.4). 
HAART fails to restore HIV-specific cytotoxic T lymphocytes (CTL) and the activity 
of HIV-specific CTL decreases after HAART-associated suppression of HIV. CTL 
are essential in controlling HIV infections. Reduced CTL activity in HAART patients 
could be secondary to an impaired production of type 1 cytokines or to a decreased 
antigenic burden.
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Figure 3.4: Immune reconstruction in HAART-treated patients (Source: Clerici et al 2002)
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3.6 IL-2: an example of key pro-inflammatory cytokines in HIV infection
IL-2 is a central regulator of T cell function. IL-2 induces proliferation and activation 
of both CD4+ and CD8+ T cells, potentiates the cytotoxicity of CD8+ T 
lymphocytes and NK cells and stimulates B cell function, thus playing a major role 
in the containment of viral infections and in the elimination of intracellular 
organisms. IL-2 production is deficient in HIV-infected individuals as well as after 
in vitro infection of peripheral blood mononuclear cells (PBMC), a defect that has 
been correlated to an increased production of IL-4 and IL-10. IL-2 expression in 
lymph nodes is barely detectable at all stages of HIV infection in both adults and 
children. In macaques, IL-2 mRNA expression early after infection has been 
correlated with SIV replication. Increased administration of exogenous IL-2 has 
been shown to prevent depletion of immature CD4+CD8+ and CD5+CD1 + 
thymocytes in the HIV-infected thymus of mice implanted with human fetal thymus 
and liver tissues without increasing viral load. In vitro, IL-2 strongly synergized with 
IL-4, causing viral production from in vitro infected mature thymocytes (an effect 
associated with increased expression of CCR5 and CXCR4). Unique among all 
cytokines, IL-2 is currently evaluated in a phase III clinical trials (Emery, 2002) for 
its potential therapeutic effect when administered with anti-retroviral therapy to 
increase the levels of circulating CD4+ T cells. IL-2 plus HAART reduced the state 
of immune activation and, in some studies, the HIV DNA content of PBMC, likely as 
a consequence of the numerical expansion of circulating CD4+ T cells.
3.7 IL-10: an example of anti-inflammatory cytokines in HIV infection
Anti-inflammatory cytokines, such as IL-4, IL-10, IL-13 and TGF downregulate both 
the innate and the adaptative immune responses. Their role in HIV infection has 
not been well understood because of frequently conflicting results on their effects 
on HIV replication depending on the model of infection and the experimental 
conditions.
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IL-10 is a cytokine mostly secreted by Th2 cells which inhibits the production of all 
proinflammatory cytokines and chemokines and the expression of costimulatory 
molecules, thus shutting-off T cell activation. IL-10 has been found to upregulate in 
vitro CXCR4, although not affecting the efficiency of viral transmission. Depending 
on the concentration of IL-10, both inhibitory and inductive effects on in vitro HIV 
replication have been observed. Inhibition of viral replication was correlated with 
the prevention of the synthesis and release of endogenous TNF and IL-6. 
However, lower concentrations of IL-10 resulted in the enhancement of HIV 
replication, an effect that has been associated with the cooperation with the 
released TNF and IL-6. However, others have shown that IL-10 inhibits in vitro HIV 
infection in macrophages that elevated IL-10 levels have been found, particularly in 
lymph nodes of HIV-infected individuals, while progression to AIDS has been 
correlated with an IL-10 promoter variant.
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3.8 Key Points
• The two major subsets of CD4 T helper cells, Th1 and Th2, have different 
patterns of cytokine production and different roles in immune responses.
• Hormones in pregnancy may contribute to the differentiation of Th cellsom one 
cytokine profile to another.
• Pregnancy results in a shift towards type 2 immunity and progesterone may be 
responsible for a type 1/type 2 switch at the maternal-fetal interface.
• Type 1-reactivity can indeed be a cause of pregnancy failure and administration
of IL-10 (Type-2) to abortion-prone mice was shown to reverse it.
• During HIV infection a shift to Type 2 immunity, even if not antigen specific,
indicates progression of HIV disease.
• Improvement in Type 1 function is dependent on the presence of a sufficient 
number of CD4+ T cells. HIV-infected people successfully treated with anti­
retroviral therapy show increased Type 1 functions and a rise in the number of 
CD4 cells.
• The introduction of different antiretroviral drugs used in combination results in 
the suppression of viral replication and a degree of immune reconstitution.
• Type 1 cytokine (IL-2) production is increased in long-term HAART individuals 
(2 years of therapy).
• No adverse effect of HIV on pregnancy outcome, but in HAART treated women
a three-fold increased risk of premature delivery has been reported.
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Chapter 4 Aims, objectives and methods
78
4.1 Aim
The aim of this thesis is to analyse the wider impact of HIV infection on 
reproductive choices and on pregnancy outcomes in HIV-infected women in 
Europe.
4.2 Objectives
The main objectives are:
—  to analyse the impact of HIV infection on couples and their reproductive 
choices;
—  to assess the interaction between HIV infection, antiretroviral therapy and 
fetal outcome, in terms of intrauterine fetal growth and birth weight; and
—  to quantify the association between HIV infection, antiretroviral therapy and
maternal outcome in terms of mode of delivery and maternal post partum
complications.
4.3 Structure of the thesis
The overall focus of the research presented in this thesis is the reproductive and 
sexual health of HIV-infected women as well as the wider impact of HIV infection 
on reproductive choices and pregnancy outcomes. Chapters 1 and 2 provide an 
introduction to aspects relating to HIV infection in women living in Europe and on 
mother-to-child transmission. Chapter 3 focuses more on the description of the 
immunology of pregnancy. This chapter reports data sources and methods for two 
different research project areas (Figure 4.1):
Survey on reproductive choices of H IV-infected women living Europe in which the 
following issues are addressed:
• dealing with an HIV diagnosis;
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• exploring sexual and reproductive health;
• knowledge of the risk of transmitting HIV;
• choices in childbearing; and
• time to conceive.
Immune response, H IV  and outcome of pregnancies, which addresses:
• pattern of cytokines over pregnancy and association with pregnancy
duration;
• intrauterine fetal growth;
• birth weight and gestational age at delivery; and
• maternal complications after delivery.
Chapter 5 reports results from the survey on reproductive choices (Project 1) and 
chapter 6 explores the possible mechanism underlying the association between 
HAART and premature delivery and pattern of cytokines in HIV-infected women 
(Project 2). Chapter 7 summarizes some of the broad conclusions of the project in 
terms of intrauterine fetal growth, birth weight and gestational age at delivery. 
Chapter 8 shows the analyses of post partum complications. Chapter 9 presents 
overall conclusions and identifies research gaps.
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4.4 Development of different projects under the ECS umbrella.
The ECS is a birth cohort study, in which infants born to HIV-1 infected women 
enrolled in pregnancy are prospectively followed according to standard clinical and 
laboratory protocols. Pregnant women are screened for HIV infection within 
standard antenatal care and those infected are invited to enroll; pregnant women 
identified as HIV-infected from before pregnancy are also invited to participate. 
Informed consent is obtained before enrolment, according to local guidelines and 
local ethics approval has been granted. The ECS was set up in 1985 to determine 
the rate of mother-to-child transmission of HIV, to identify risk factors associated 
with mother-to-child transmission and to investigate the natural history of paediatric 
HIV disease; centres from Spain, Italy, the United Kingdom, Germany and Belgium 
have participated since the study started, with centres from Sweden (1986), the 
Netherlands (1987), Poland (1989), Denmark (1995) and Ukraine (2000) joining 
subsequently. In addition to epidemiological analyses, the data reported to the 
ECS provides the opportunity to investigate more specific, clinically based topics 
and where appropriate ECS also responds to clinical concerns by initiating or 
supporting ad-hoc additional research projects .
The ECS involves now 25 centres from European countries (Appendix I). Pregnant 
HIV-infected women are enrolled in the study and their children followed from birth 
according to standard clinical and laboratory protocols. Women having spontaneous 
abortions, or terminations of pregnancy are not included in the study. Obstetricians 
and/or paediatricians at enrolment and at each subsequent follow-up visit complete a 
range of data collection forms. These forms are then returned to the co-ordinating 
centre in London, where the data is coded and entered into an Access database. 
Data checking programmes have been in operation since the study started to verify 
the quality of the data received, which is also checked manually during the processes 
of coding and entry. There is constant liaison with the key physicians in each centre
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to address any data queries and to maintain enrolment. In addition to the routine data 
quality control, specific checking of the relevant data was carried out prior to the 
analyses presented here.
Between 1998 and 2004, 19 clinicians in obstetric centres in Italy, Spain, Sweden, 
UK, Belgium, Germany, Switzerland, Holland and Denmark were asked to join 
different projects under the ECS umbrella and obtained site-specific research ethics 
committee approvals.
The project of this thesis involved HIV-infected pregnant women and also HIV- 
infected non-pregnant women and HIV-uninfected pregnant controls; setting up the 
clinical network meant using the ECS infrastructure and the obstetric ECS arm, but 
also involving additional clinicians -  mainly infectious disease specialists and 
immunologists in different centres .
4.5 The researcher’s role
As this work was carried out within the framework of a large and on-going prospective 
study, it is necessary to clarify my role in the research. With regard to the ECS, I had 
limited involvement in the data, questionnaires and data entry, but liaised with 
obstetricians regarding data queries specific to the projects detailed in this study. I 
performed the specific analysis related to birth weight and gestational age at delivery 
on the ECS data in order to complete my research on intrauterine growth. In relation 
to the ECS, I also collaborated in the preparation of various manuscripts for 
publication (Appendix IV).
All the different projects were nested within the large ECS study. Figure 4.2 shows 
data sources within different research areas.
I was the lead researcher in the reproductive survey, designing the questionnaire 
and being responsible for the survey administration (correspondence, distribution
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of questionnaires and reminders and so forth). I created the database, analyzed 
results and I will prepare the manuscript for publication. I was the lead researcher 
on the project relating to the “Immune response and pregnancy outcome” 
collaborating with Prof Mario Clerici in Milan. I was responsible for selection of 
clinical cases and blood samples collection, organization of laboratory materials 
and administration, (the organization of the provisioning of the laboratory and 
payment therefore).
A biologist researcher performed cytokine in vitro production testing and I spent a 
fair amount of time helping in setting up methods and preparing PBMCs from fresh 
samples. I created the database and entered all the data and sought statistical 
advice in order to discuss different statistical options and programmes. I also 
prepared a manuscript for publication (Appendix IV).
Data for two different projects on maternal complications after delivery and on the 
fetal intrauterine growth were all retrospectively collected. Although I was the key 
researcher involved, data relating to uninfected controls were collected by different 
networks and used within this study. I was responsible for administration, 
designing the questionnaires, data collection and management (database 
formation and data entry). I also prepared a manuscript for publication (Appendix 
IV).
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Chapter 5 Survey on reproductive choices and outcome
Sum m ary This project aimed to document the reproductive experience of HIV- 
infected women living in Europe. It was intended that HIV-infected women and 
their carers would be able to use the results to advocate change in national policies 
and practices that would improve their reproductive outcome and available 
healthcare choices.
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5.1 Methods
(i) Objective
To explore the impact HIV infection on women’s sexual and reproductive 
decisions and choices by investigating:
—  factors affecting decision to become pregnancy;
—  their relationships and experience with HIV in relation to their desire of
maternity;
—  their ability to conceive as measured by self-reported length of time to 
conceive;
—  their obstetrical history, contraception and reproductive health problems; 
and
their experiences of reproductive counselling.
(ii) Study Design and data source
This survey was carried out to obtain information on social, demographic and basic 
reproductive health characteristics of HIV-infected women living in Europe. The 
chosen method was a self-completed anonymous questionnaire to be completed by 
HIV-infected women attending an obstetric and gynaecologic unit or outpatient 
infectious disease unit. The aims of the survey were described on the front page of 
the questionnaire. Clinicians working in major centres of HIV expertise (many of which 
were participating in the European Collaborative Study or national equivalents 
Appendix I), were asked to identify women infected with HIV infection and to discuss 
with them the rationale and the aims of the project. The questionnaire was sent to 
clinicians and, where required, we asked them to translate it into the national 
language. A pilot phase including 100 women was carried out in order to develop the 
questions on sexual health and health care through practice interviews. The
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questionnaire was finalized on the basis of the experience from the pilot. During a 
training period, clinicians were instructed how to ask women to participate and the 
meaning and importance of confidentiality was discussed. The final version of the 
questionnaire consisted of 47 multiple choice and semi-structured questions 
(Appendix II). Completion of the form was taken as consent to participate; non­
participation did not affect their care. HIV infected pregnant women were also 
enrolled in the ongoing ECS study.
(iii) Study population
Four hundred and three women in 5 European countries were interviewed between 
July 2003 and July 2004. It is not possible to calculate the response rate because 
HIV infected women were left free to pick up their own copy from the reception 
desk. The women were asked questions about their reproductive health 
experiences since their HIV diagnosis, starting with the circumstances of their 
diagnosis, their health, sexual relationships, and decisions about reproduction and 
the counselling received and time taken to conceive. All the women interviewed 
knew that they were HIV-infected. Ten per cent of the women interviewed were 
pregnant and had known their HIV status for over a year. Hundred women were 
diagnosed over 10 years ago.
(iv) Statistical Analysis
Close-ended questions resulted mainly in quantitative analyses. Access 2000 was 
used for data entry and data management and for statistical analyses. Univariable 
and multivariable logistic regression and survival analyses (Kaplan-Meier) were 
performed using STATA software.
5.2 Clinical characteristics
Four hundred and three HIV-infected women were responded from 5 European 
countries (Table 5.1) but some of these women did not complete the
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questionnaires in full and some of the results are therefore not based on the full 
403 questionnaires. The majority of these women (96%) reported to be in a long­
standing relationship with a median duration of 74 months. Most women were not 
pregnant (282/403) at the time of completion of the questionnaire.
Table 5.1 European centres participating
Centre Women enrolled
Barcelona (Spain) 65
Milan, Naples, Turin (Italy) 91
Odessa (Ukraine) 63
Paris (France) 73
Warsaw (Poland) 111
Total 403
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Table 5.2: Socio-demographic characteristics of respondents, by pregnancy status
Country of birth Not pregnant Pregnant Total
North Africa 4 (2%) 2 (2%) 6 (2%)
Sub-Saharan Africa 22 (12%) 12 (13%) 34 (12 % )
Europe 153 (84%) 75 (8.3% ) 228( 84%)
Other 4 (2%) 1 (1%) 5 (2 %)
Total (missing 130) 183(100%) 90 (100%) 273 (100%)
chi2(3) = 0.4647 Pr = 0.927
Age Not pregnant Pregnant Total
21-29 71 (30%) 24 (22%) 95 (27%)
30-35 51 (21%) 36 (33%) 87 (25%)
36-40 81 (34%) 41 (38%) 122 (35%)
40-53 36 (15%) 8 (7%) 44 (13%)
Total 239 (100%) 109 (100%) 348 (100%)
chi2(3) = 0.65 Pr = 0.1
Profession Not pregnant Pregnant Total
Manual 15 (13%) 15 (27%) 30 (18%)
Nonprof/non man 55 (48%) 18 (33%) 73 (43%)
Professional 25 (22%) 7 (13%) 32 (19%)
Housewife/
unemployed
20 (17%) 15 (27%) 35 (20%)
Total 115 (100%) 55 (100%) 170 (100%)
chi2(3) = 9.6138 Pr = 0.022
Sexual orientation Not pregnant Pregnant Total
Heterosexual 174 (76%) 90 (83%) 264 (78%)
Homosexual 51 (22%) 18 (17%) 69 (20%)
Bisexual 5 (2%) 0 5 (2%)
Total 230 (100%) 108 (100%) 338 (100%)
chi2(2) = 3.9948 Pr = 0.136
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Table 5.2: Socio-demographic characteristics of respondents, by pregnancy status
Marital Status Not pregnant Pregnant Total
Cohabiting 101 (42%) 38 (35%) 139 (40%)
Divorced 7 (3%) 5 (4%) 12 (4%)
Married 87 (37%) 57 (52%) 144 (40%)
Separated 14 (6%) 2 (2%) 16 (5%)
Single 4 (2%) 2 (2%) 6 (2%)
Widowed 13 (5%) 1 (1%) 14 (4%)
Other 12 (5%) 4 (4%) 16 (%5)
Total 238 (100%) 109 (100%) 347 (100%)
chi2(6) = 12.9183 Pr = 0. 044
5.2.1 HIV diagnosis
Seventy percent (280/403) of the women had a positive result when first tested for 
HIV. Reasons for testing were, in most of cases, related to health problems or the 
result of having an HIV-infected partner (Figure 5.1). Overall, heterosexual 
infection was reported as being the predominant mode of acquisition of infection 
(190/344 - 55%) with 39% of these women (74/190) infected by their current 
partner, and 48% (92/190) by a previous HIV-infected partner. Illicit drug use was 
still an important mode of acquisition (28%) but the majority of such women had 
had their first positive HIV test before 1996 (Table 5.3).
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Figure 5.1: Reasons for testing reported by 399 respondents
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Table 5.3: HIV Characteristics of respondents, by pregnancy status
Reason for first 
testing
Not pregnant Pregnant Total
Pregnancy 30 (13%) 19 (18%) 49 (14%)
Routine health 
care
46 (19%) 15(14%) 61 (18%)
partner infected 58 (25%) 24 (22%) 82 (24%)
Other 102 (43%) 50 (46%) 152 (44%)
Total 236 (100%) 108 (100%) 344 (100%)
chi2(3) = 2.8816 Pr = 0.410
Tested before Not pregnant Pregnant Total
No previous 
testing
165 (74%) 68 (67%) 233 (72%)
Previously tested 58 (26%) 34 (33%) 92 (28%)
Total 223 (100%) 102 (100%) 325 (100%)
chi2(1) = 1.8501 Pr = 0.174
Mode of 
acquisition
Not pregnant Pregnant Total
Sex with current 
partner
54 (23%) 20 (18%) 74 (21%)
Sex with HIV man 57 (24%) 35 (32%) 92 (27%)
Sex I DU man 6 (2%) 3 (3%) 9 (3%)
Sex I DU partner 11 (5%) 4 (4%) 15 (5%)
Blood 10 (4%) 2 (2%) 12 (3%)
IDU 69 (30%) 28 (26%) 97 (28%)
High prevalence 
country
5 (2%) 3 (3%) 8 (2%)
Do not know 24(10% ) 13(12%) 37 (11%)
Total 236 (100%) 108 (100%) 344 (100%)
chi2(7) = 4.5903 Pr = 0.710
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Table 5.3: HIV Characteristics of respondents, by pregnancy status
HIV drugs Not pregnant Pregnant Total
No Drugs 63 (27%) 19 (17%) 82 (24%)
Monotherapy 9 (4%) 18 (17%) 27 (8%)
Double therapy 54 (23%) 28 (26%) 82 (24%)
HAART 108 (46%) 44 (40%) 152 (44%)
Total 234 (100%) 109 (100%) 343 (100%)
chi2(3) = 18.7353 Pr = 0.000
HIV symptoms Not pregnant Pregnant Total
No symptoms 92 (51%) 68 (77%) 160 (59%)
Mild symptoms 24 (13%) 16 (18%) 40 (15%)
Severe symptoms 65 (36%) 4 (5%) 69 (26%)
Total 181 (100%) 88 (100%) 269 (100%)
Pearson chi2(2) = 30.6370 Pr = 0.000
5.2.2 Relationship
Table 5.4 shows characteristics of the women’s relationships in relation to their 
pregnancy status. Seventy per cent of the women (283) were currently cohabiting 
or married and 118 had a previous child with the current partner. Only 308 
responded to the question about the HIV status of their partner: 145 (47%) had an 
HIV-uninfected partner, 123 (40%) had an HIV-infected partner, and 40 (13%) did 
not know whether or not their partner was HIV-infected. Fourteen women (5%) 
stated that their partners were not aware of their HIV status and six of these 
women were pregnant.
Half of the women with a current HIV-infected partner (72/123) were diagnosed 
with HIV after their partners had been. The majority (209/283 -  74%) of the long 
standing couples (married +cohabiting) couples had children together or were 
expecting a baby at the time of completion of the questionnaire.
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Table 5.4: Characteristics of respondents relationships, by pregnancy status
Partner aware Not pregnant Pregnant Total
No 8 (4%) 6 (6%) 14 (5%)
Yes 180 (96%) 96 (94%) 276 (95%)
Total 188 (100%) 102 (100%) 290 (100%)
chi2(1) = 0.3810 Pr = 0.537
HIV status 
partner
Not pregnant Pregnant Total
Uninfected 83 (47%) 62 (68%) 145 (54%)
Infected 94 (53%) 29 (32%) 123 (46%)
Total 177 (100%) 91 (100%) 268 (100%)
chi2(1) = 10.9183 Pr = 0.001
First to be 
identified
Not pregnant Pregnant Total
Woman 37 (43%) 14 (47%) 51 (44%)
Her partner 49 (57%) 16 (53%) 65 (56%)
Total 86 (100%) 30 (100%) 116 (100%)
chi2(1) = 0.1198 Pr = 0.729
5.2.3 Reproductive health problems
One quarter of women described their current HIV symptoms as “severe”, but most 
of the women reported to be asymptomatic. Most of the women recalled the date 
that they commenced medication and the type of medication that they took. 
Eighty-two women (20%) did not use any antiretroviral drug at the time of the 
interviews (Table 5.2) and only 152 women were on combination therapy including 
three or more drugs. Of the 152 (44%) women on combination therapy, 110 
(110/152 -  72%) had switched drugs and the reason recalled for this was 
pregnancy (20%) or decline in CD4 count/rising titers of HIV viremia.
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All the health conditions women described in their interviews were self-defined and 
were in terms of symptoms rather than of named diseases. Symptoms were 
mostly mentioned as the reasons for testing (fatigue, lymph nodes, surgery, etc) 
and in the section of the questionnaire exploring gynaecologic problems.
Over a third of women in the survey reported genital tract infections to be the most 
common gynaecological problem. Many women interviewed described symptoms 
of the reproductive tract disorder (for example: fibroids, ovarian cysts, abdominal 
pain) but only non-pregnant women complained about irregular menstrual periods 
in relation to their HIV infection status (35/227 -  15%).
5.2.4 Fertility
One hundred and twenty-one (30%) respondents were pregnant when they took 
part in the survey. Very few women reported their profession and within these, 
housewives, unemployed and women having a manual job were more likely to be 
pregnant (Table 5.2). Sixty women (60/121 -  49%) planned their pregnancy and 
24 women (21%) despite not having not planned their pregnancies declared 
themselves wanting a pregnancy. Of the 60 women who reported to have planned 
the pregnancy, 35 (58%) women conceived in less than six months, with nine 
taking only one month. For the 24 women who were desirous of a pregnancy but 
who were not specifically planning it, the time taken to conceive is irrelevant but it 
can be assumed that they did not have any difficulty in conceiving. Thirty-seven 
women had an undesired pregnancy but intended to take the pregnancy to term. 
Figure 5.2 shows the distribution of planning status of pregnancy according to living 
children. Around 97 pregnant women were aware of the HIV infection status of their 
partner and 64 (66%) of these reported to be in a relationship with an uninfected 
man. Out of 64 couples, 22 avoided the risk of infecting the uninfected partner by 
means of autoinsemination.
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Figure 5.2: Distributions of planning status of pregnancies according to living children
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Amongst the 226 non pregnant women, 39% (90/226) expressed themselves to 
desire a baby but only 34 women were actually trying for a baby when responding 
to the questionnaire; nearly half of them (15) reported to have been trying for more 
than 18 months at the time of completing the questionnaires. The respondents 
were adequately and timely counselled, receiving information mostly from 
Infectious Disease specialists. Very rarely (5%) they received advice from an 
obstetrician or gynaecologist before conception. Usually they were referred to the 
Obstetrics Unit only when they requested it after a long period of attempting to 
conceive or when the pregnancy was confirmed.
Forty-five HIV-infected pregnant women (46%) said they did not use any barrier 
contraceptive during pregnancy. Within this sub-group, 22 had an HIV-infected 
partner and the reported reasons for failure to use a prophylactic were abstinence 
(9), because both partners were already infected (4), because of low infectivity due 
to the woman’s low viraemia (9). In the sub-group of women (23) who had an 
uninfected partner, reasons given for not using a prophylactic were latex allergy 
(8), partner’s choice (10) and sexual abstinence (5).
To assess the size of the problem relating to difficulties in conceiving, it is helpful to 
look at the two groups of women separately: among all pregnant women who 
planned their pregnancy (60) five reported to have needed assistance to conceive 
by monitoring the ovulation period and five by means of in vitro fertilisation 
programmes. An estimated infertility rate in this population would thus be about 
sixteen percent (10/60). Among the 34 non pregnant women who reported to be 
currently trying for a baby at the time of responding to the questionnaire, nearly half 
(15/34 44%) reported to have been trying to conceive for more than 18 months. An 
overall infertility rate could then possibly be calculated as 26% (25/94) taking into 
account only those women in both groups who are planners (60 in the pregnant
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group and 34 in the non pregnant women), and who had problems (10 in the 
pregnant group and 15 in the second group).
5.2.5 Obstetrical history and contraception
HIV-infected women reported their previous obstetric experience in relation to their 
current partner and their awareness of their own HIV status. Most of the women 
(275/403) had been pregnant before. Whilst 160 (58%) of these women had had a 
previous successful outcome, 48 (17%) women had had a previous miscarriage 
and 67 (25%) women had had a voluntary termination. Figure 5.3 shows the 
interval between a previous event and the current pregnancy and shows that there 
is little difference in the time between those women having had a previous negative 
event (voluntary termination, extrauterine pregnancies and miscarriages) and those 
having had a successful pregnancy (p=0.6679).
Compared to non-pregnant women, pregnant women were more likely to have an 
uninfected partner (p 0.002) and to have had a previous unsuccessful pregnancy 
(p 0.0171). However, this was not the case for the 22 African women who were the 
small group of women with three, four or five children.
Of the 67 women who had opted for a voluntary termination in the past, 
approximately half (33) reported to have done so as a result of their awareness of 
their HIV status. Twenty-six of these women were pregnant when they completed 
the questionnaire and 14 had changed partners since the termination.
We asked the respondents to provide information on the history of contraceptive 
methods that they had adopted. This information is shown in Figure 5.4.
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Figure 5.3: Interval between any obstetrical event and the current pregnancy
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Figure 5.4: Distributions of current contraceptive methods
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5.2.6 Factors associated with achieving a pregnancy
In a multivarible analysis (Table 5.5) to assess the effect of selected factors in the 
HIV infected population, maternal well-being and an uninfected partner were 
strongly associated with pregnancy. Pregnancies were more likely to occur in 
women with no previous livebirths, although this appears to be a less important 
factor.
Although having an HIV infected partner significantly reduced the risk of being 
pregnant, it is unclear whether this was a conscious decision.
As previously mentioned, having had a previous negative experience (miscarriage, 
termination or extrauterine pregnancy) or a successful pregnancy, did not change 
the length of time to conceive.
The use of highly active antiretroviral therapy was more common in the pregnant 
group; this variable was not included in the logistic model because it is correlated 
to maternal well-being.
Table 5.5: Logistic regression: factors associated with being pregnant
Pregnant AOR P 95%CI OR P 95% Cl
HIV-infected partner 0.44 0.010 .23-.82 0.46 0.003 .28-.76
One baby at home 0.55 0.064 .30-1.03 0.53 0.017 .31-.89
Maternal well-being ( Any 
HIV symptom)
0.38 0.032 .16-.92 0.33 0.000 .14-.52
Heterosexual route 0.97 0.06 .89-1.07 0.99 0.09 93-1.06
Married or cohabiting 0.83 0.090 .68-1.02 0.94 0.043 82-1.08
Profession 1.1 0.30 .69-1.96 0.94 0.025 82-1.08
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5.3 Conclusions
All women had access to antiretroviral treatment to control their disease and to 
reduce the risk of HIV transmission to their infants. The study showed that most 
women are found to be infected on the basis of their first HIV blood test and 
showed poor knowledge of HIV transmission or risk before diagnosis with HIV.
Reproductive counselling after their HIV diagnosis was rarely provided by 
obstetricians but was commonly provided by infectious disease specialists and had 
had a positive impact on those women who had benefited from such counselling.
These results do not indicate a general difficulty in achieving conception with most 
of these HIV-infected women having short time to conceive.
The findings of this survey do not necessarily reflect the views or experience of 
young women, as only about 5 per cent of participants were under 25 years of age. 
Furthermore all women who participated in the study attended an Obstetric and 
Gynaecology Unit, and may thus be better informed and more confident about 
living with HIV than women in the general HIV infected population.
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5.4 Key points
• The majority of HIV-infected women were in a long-standing relationship at 
the time of the survey.
•  Heterosexual infection was the leading mode of acquisition with 39% of 
heterosexually infected women infected by their current partner.
• One quarter of women interviewed reported to be suffering severe (self­
defined) HIV symptoms.
• One quarter of women did not use any antiretroviral drug.
• Genital tract infections was the most common gynaecological problem.
• Non-pregnant women (15%) reported irregular menstrual periods since they 
were HIV-infected.
• Thirty percent of the respondents were pregnant, half of whom reported to 
have specifically planned the pregnancy.
• Pregnancies were more likely to occur in women with no previous livebirths 
and in those with an uninfected partner.
• Time to conceive was less than six months in 35/60 pregnant women, but 
was more than 18 months for 15/34 non-pregnant women who were 
currently trying for a baby.
• Contraception was widely used with around 20% women having used 
hormonal methods.
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Chapter 6 Immunology of HIV and outcome of pregnancy
Sum m ary  Antiviral therapy-associated modulation of type 1 and type 2 cytokines is 
associated with a negative outcome of pregnancy in HIV-infected women. HIV- 
infected, HAART-treated pregnant women are at increased risk of premature 
delivery. We investigated the mechanism of this phenomenon analysing IL-2 and 
IL-10 production by PBMCs in HIV-infected, HAART-treated women followed 
longitudinally during the course of pregnancy.
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6.1 Methods
(i) Objective
To understand the mechanism that could explain the association between 
immunological changes induced by antiretrovirals and maintenance of pregnancy.
(ii) Study design and data source
Prospectively collected data and experimental laboratory-based analysis. HIV 
infected pregnant women enrolled in this project were part of the ongoing 
longitudinal ECS study; samples were only collected in two main centres close to 
the laboratory (Milan, Turin) given the need to use fresh samples for the 
preparation of peripheral blood mononuclear cells (PBMCs). The size of the study 
was determined by the limited availability of funding .
(iii) Study population
Between January 2001 and December 2002, 57 HIV-infected women were 
identified, and followed during pregnancy according to local practice in two main 
Italian maternity centres. Full ethics approval was obtained at centre level and 
maternal clinical and laboratory information collected during pregnancy, and at the 
time of delivery. All women were followed according to a standard clinical and 
laboratory protocol. At delivery, neonatal details were recorded. All women gave 
written consent for the use of the samples for research purposes. The final 
analyses included 49 women who were tested three times during gestation (first, 
second and third trimester); with production of type 1 (IL-2) and type 2 (IL-10) 
cytokines by PBMCs evaluated in the presence or absence of stimulation (basic 
value, unspecific phytohaemogglutinin-PHA response and HIV specific-ENV 
response). Levels of cytokines thus measured were related to the use of anti­
retroviral therapy, CD4 count, plasma RNA viral load and delivery details, including 
premature delivery.
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Treatment administration for each woman was categorized as ever/never HAART 
at any point during gestation and premature delivery was defined as birth before 37 
weeks of gestation.
Mothers were screened at the third trimester visit for Group B streptococcus (GBS) 
by lower vagina and rectum swab, for bacterial vaginosis by vaginal swab, for HPV 
and Chlamydia trachomatis by cervical swab, and for Mycoplasma hominis by DNA 
PCR assay on cervical and urethral swab. Exclusion criteria were hepatitis B and 
C co-infection, multiparous, multifetal gestation, previous surgery on the uterine 
cervix, maternal smoking and illicit drug use as risk factors for premature delivery.
Whole blood was collected by venipucture in Vacutainer tubes containing EDTA 
(Becton Dickinson Co., Rutherford, NJ). The samples were taken in the first, 
second and either the third trimester of pregnancy or when the woman presented in 
labour. Peripheral blood mononuclear cells (PBMCs) were separated on 
lymphocyte separation medium (Organon Teknika Corp., Durham, NC) and 
washed twice in PBS, and the number of viable leukocytes was determined by 
trypan blue exclusion and a hemocytometer. The samples were kept at room 
temperature and were analysed within 24 hours. We adopted methodology used to 
assess the functioning of the immune system in HIV infection (Clerici, 2002).
(iv) In vitro cytokine production
PBMCs were resuspended at 3x106/ml in RPMI 1640 and were incubated in the 
presence or absence of PHA or ENV at 37°C in a moist, 7% C 02 atmosphere. 
Supernatants were harvested after 48 hours for PHA stimulation or after five days 
for ENV. Production of type 1 (IL-2) and type 2 (IL-10) cytokines by PBMCs was 
evaluated with commercial ELISA kits (ENDOGEN). All test kits were used 
following the procedures suggested by the manufacturer. Cytokine production was
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calculated from a standard curve of the corresponding recombinant human 
cytokine in each case.
(v) Statistical analysis
To represent the individual trends of the repeated cytokine measurements within 
women over gestation, slopes for IL2-Pha, IL2-Env, IL10-Pha and IL10-Env levels 
were estimated by fitting linear regression lines through available measurements 
across gestation for each woman. Median slope values were compared by pre­
term birth status and treatment group, using Wilcoxon rank sum tests. Regression 
analyses were used to quantify the association between cytokine slope values with 
pre-term delivery status. Extension to multiple regression allowing for treatment 
was used to clarify whether the relationships of cytokine slope value and pre-term 
delivery status could be explained by a treatment effect. Analyses were performed 
using STATA 7 statistical software.
6.2 Clinical characteristics of women enrolled
Fifty-seven women were initially involved in this study. The final analysis involved 
747 blood samples (249 per trimester) from 49 women, with 147 visits. Problems 
with blood collection led to the exclusion of four patients from the analyses. A 
further four patients were excluded due to GBS positivity (n= 2) and severe 
intrauterine growth restriction (n=2).
Baseline characteristics of women by use of antiretroviral therapy are shown in 
Table 6.1. Twenty-six women were on HAART, most (22/26, 85%) of whom 
received a PI. The immunological status of mothers did not differ by treatment 
received, as CD4 cell count and RNA viral load at enrolment were similar in both 
groups. All women were primiparous and all tested negative for STDs (bacterial 
vaginosis, HCV, HBV, HPV, Chlamydia trachomatis, Mycoplasma hominis). Thirty- 
three women (67%) delivered by elective caesarean section at term; two women
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delivered vaginally (27 weeks and 24 weeks) and 14 (29%) had an emergency 
caesarean section due to premature labour before the planned date for the elective 
procedure.
Preterm delivery (delivery before 37 gestational weeks) was more likely to occur in 
women receiving HAART (X2=4.5 p=0.03) than in those not receiving HAART and 
occurred before 34 weeks in eight out of the 16 cases. Babies born to HAART 
treated women had a significantly lower mean birth weight (p=0.004) than those 
born to women not treated with HAART. No infants were subsequently diagnosed 
as being HIV-infected
6.3 Effectiveness of HAART
During the course of pregnancy, all women on HAART showed a progressive 
increase in their CD4 cell count and a decrease in the level of RNA viremia. The 
median CD4 cell count increased from 438 cells per ml (range 100-1187) during 
the first trimester to 467 cells per ml (range 84-14390) during the second trimester 
and 448 cells per ml (range 141-1177) at delivery. The median RNA viral load 
decreased from 19,589 copies per ml (range 50-190,000) during the first trimester, 
to 6,158 (range 50-34,775) in the second trimester and 2007 copies per ml (range 
50-15,000) at delivery. The immune status of these women was relatively intact 
and the RNA viremia was modest, with about half of them having undetectable 
viremia at birth. Those women in the never HAART category showed a steady level 
of CD4 and of RNA viremia .
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Table 6.1: Clinical characteristics of 49 HIV-infected pregnant women by use of 
HAART
Non-HAART 
(nr 23)
HAART 
(nr 26) P
Maternal age in 
years (mean-, SD)
29 (3,4) 28 (4,1) 0.16
Median gestational 
age at delivery 
(range)
37(34-39) 36 (24-39) 0.04
Preterm delivery 4/23 12/26 0.03
Mean birth weight in 
gr (SD)
2680 (674) 2514 (366) 0 .02
Median CD4 cell 
count at entry 
(range)
400 (178-850) 439 (84-1093) 0.60
Median RNA VL at 
entry (range)
13718
(max 190,000)
19589
(max 34,775)
0.12
Median CD4 cell 
count at delivery 
(range)
423 (158-950) 467(141-1177) 0.50
Median RNA VL at 
delivery (range)
10158
(max 180,000)
2007
(max 50,15000)
0.23
~ m ean and median did not differ
6.4 Cytokines slopes over pregnancy
Production of Type 1 (IL-2) and Type 2 (IL-10) by PBMCs by trimester of 
pregnancy is shown in Figures 6.1 and 6.2. It is noteworthy that IL-10 patterns 
over pregnancy are less sharp than those of IL 2 ones, but the scale for IL-10 is 5 
times that for IL-2, which dulls the response seen. Therefore slopes were 
calculated to provide a similar unit in response for IL-2 and IL-10. Trends of IL-2 
(PHA and env-stimulated) and IL-10 (PHA and env-stimulated) measurements 
within women over gestation are shown in Figure 6.3. There were no statistically
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significant differences by prematurity in the median values for slopes of any of the 
cytokines and only env-stimulated IL-10 production differed significantly by 
treatment group (p=0.043). However, Figure 6.3 shows that the slope of PHA- 
stimulated IL-2 is positively associated with a preterm delivery (p=0.008) and with 
treatment although the latter association did not reach statistical significance 
probably due to lack of power with small numbers. Env-stimulated IL-10 was 
negatively associated (decrease over gestation) with preterm delivery (p=0.34) and 
with treatment (p=0.007). Values are shown in the table following the figure.
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Figure 6.1: Production of Type 1 (IL-2) cytokines by PBMCs by trimester of pregnancy
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Figure 6.2: Production of Type 2 (IL-10) cytokines by PBMCs by trimester of pregnancy
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Figure 6.3: Cytokine slopes over pregnancy (values of the slopes are shown in the following table) 
(a) by pre-term delivery (b) by treatment
pha Preterm 
pha Term 
env Preterm 
env Term
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Values for figure 
6.3a
Pre-term 
delivery 
Mean (SD)
Term delivery 
Mean (SD)
*P
IL2-pha 4.9 (13) 0.36 (3.8) 0.10
IL2-env -0.14(0.37) -0 .15(0 .67) 0.33
IL10-pha -21 (51) -13.46 (83) 0.30
IL10-env -14.35(85) 9.1(73) 0.34
Values for figure 
6.3b
HAART 
Mean (SD)
Non HAART 
Mean (SD)
P
IL2-pha 3.0(10.6) 0.31 (3.0) 0.23
IL2-env -0.132 (0.42) 0.26 (0.72) 0.23
IL10-pha -33.8(97) 1.49(43.8) 0.17
IL10-env -12.2 (85) 16.6 (66.7) 0.043
To assess the independent contribution of cytokine slopes and HAART on the risk 
of premature delivery, all three variables were included in a regression analysis 
(Figure 6.4 and Table 6.2). HAART and IL-10 env slopes were not significantly 
associated with the risk of preterm delivery, in either univariate or multivariate 
analysis, but each unit increase in the slope of IL-2-pha was associated with a 
significant eight percent increase in the risk of preterm delivery (AOR 1.08, 
p=0.05). This confirms a dominant effect of Type 1 cytokines on adverse 
pregnancy outcome, while there is no evidence of an additional independent effect 
of HAART on the risk of premature delivery.
The relation between preterm delivery and IL2 / IL10 was confirmed by a significant 
interaction between treatment and IL2 slope (LRT X2 = 6.37, p=0.04) and treatment 
and IL-10 slope (LRT X2 = 12.45, p=0.006).
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Figure 6.4
Regression analyses: slope values of PHA-IL-2 and ENV-IL-10 
over gestational age by delivery
100
50
0
(A
O
f  -50 
>
2.-100
o  
cn
-150
-200
-250
PHA-IL2=0.36+(4.55)*(delivery=0/1)
p=0.008
V   ^ENV-IL10=9.1+ (-23.54)*(delivery=0/1) 
s *  p=0.07
IL2-PHA-pre
IL2-PHA-term
- IL10-ENV-pre 
— -  IL10-ENV-term
Gestation weeks
Table 6.2: Risk of pre-term delivery by cytokine slopes over pregnancy allowing 
for HAART
OR (95 %CI),p AOR (95% Cl ),p
No treatment 1 1
HAART 1.27 (.52-3.0) 0.59 96 (0.37-2.52) 0.95
IL2-pha 1.07(1.00-1.15) 0.032 1.08(1.0-1.17) 0.05
IL10-env 0.99 (.99-1.00) 0.174 0.99(0.99-1.00) 0.58
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6.5 Conclusions
Results from this descriptive study suggest that HAART-induced 
immunomodulation, which is beneficial for HIV disease, is significantly associated 
with a higher incidence of unfavourable pregnancy duration.
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6.6 Key points
• Preterm delivery (delivery before 37 gestational weeks) was more likely to 
occur in women receiving HAART (X2=4.5 p=0.03) than in those not 
receiving HAART
• During the course of pregnancy, all women on HAART showed a
progressive increase in their CD4 cell count and a decrease in the level of
RNA viremia
• Slopes were calculated to provide a similar unit in response for IL-2 and IL- 
10 as the scale for IL-10 is 5 times that for IL-2.
• There were no statistically significant differences by prematurity in the 
median values for slopes of any of the cytokines and only env-stimulated IL- 
10 production differed significantly by treatment group (p=0.043).
• Env-stimulated IL-10 was negatively associated (decrease over gestation) 
with preterm delivery (p=0.34) and with treatment (p=0.007).
• To assess the independent contribution of cytokine slopes and HAART on 
the risk of premature delivery, all three variables were included in a 
regression analysis
• HAART and IL-10 env slopes were not significantly associated with the risk 
of preterm delivery, in either univariate or multivariate analysis, but each 
unit increase in the slope of IL-2-pha was associated with a significant eight 
percent increase in the risk of preterm delivery (AOR 1.08, p=0.05).
• This confirms a dominant effect of Type 1 cytokines on adverse pregnancy 
outcome.
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Chapter 7 HIV infection affecting fetal intrauterine growth
Sum m ary Infants born to HIV infected mothers reportedly are of lower birth weight 
than those of HIV uninfected mothers. To analyse intrauterine growth profiles of 
infants born to HIV infected mothers allowing for antiretroviral therapy, in 
comparison to a healthy, uninfected population we prospectively collected 
data(head circumference, femur length, abdominal circumference) for 316 HIV 
infected women on intrauterine parameters.
From the large ECS population, birth weight was analysed and compared to the 
British standard to add one more piece of information to the debate on maternal 
treatment and gestational age at delivery
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7.1 Methods
(i) Objectives
To investigate whether HIV infection in a pregnant woman affects the growth of her 
fetus, we analyzed intrauterine growth profiles of infants born to HIV-infected 
mothers compared to a healthy, uninfected population.
(ii) Study design and data source
Retrospective and prospective observational studies. Clinicians who participate in 
the ECS longitudinal study, were asked to collect data, where feasible, on 
ultrasound intrauterine longitudinal measurements. The sample size was 
determined on the availability of data.
(iii) Study population
Data were collected on 316 HIV-infected pregnant women who were referred to 
four obstetrical reference centres in Italy between 1990 and 1999. In each centre, 
after giving consent, women were prospectively monitored according to a standard 
protocol. Information collected included current antiretroviral treatment, CD4 cell 
count, and injecting drug use (IDU) history. IDU was classified into never, ex and 
current IDU on the basis of self-report. Delivery and neonatal characteristics 
included mode of delivery, gestational age, gender, birth weight, presence of 
congenital abnormalities and neonatal complications. Laboratory tests, including 
serology and CD4 cell count measurements, were carried out locally. Maternal 
CD4 cell counts nearest the time of delivery were used. Maternal HIV RNA was 
available only for a few women, and could thus not be used in further analyses. 
Mothers enrolled were asymptomatic and all were classified in stage A of disease 
according to the CDC classification. Antiretroviral therapy prophylaxis to reduce 
mother-to-child transmission was not an option for 127 patients who delivered 
before 1995.
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Perinatal outcome was recorded in terms of birth weight, gestational age at 
delivery, premature delivery (before 37 weeks of gestation), and presence of 
congenital anomalies. Small for gestational age fetuses (SGA) were defined on the 
basis of an abdominal circumference below the 10th centile for gestation. A child was 
classified as infected after the detection of virus or antigen in at least two blood 
samples or persistence of antibody beyond 18 months of age; a child was 
presumed uninfected if at least two blood samples were antibody-negative and if 
no virus or antigen was ever identified.
Fetal growth was assessed by ultrasound measurements of femur, head and 
abdominal circumference and serial measurements were used to model individual 
growth shape (Hooper, 2002; Todros, 1987). High quality sonographic scanners, 
with 3.5-5.0 MHz convex transducers, were used in all centres. Measurements 
procedures were the same in all centres and followed international standards: head 
circumference was measured on a fronto-occipital transverse section at the level of 
the upper third of the talami, the abdomen was measured on transverse section at 
the mid-portion of intrahepatic umbilical vein, the femur length (FL) was measured 
from the greater trochanter to the lateral condyle.
The number of examinations varied depending on individual obstetric management 
and we included infected mothers-to-be with a minimum of two longitudinal 
ultrasound assessments in order to evaluate the longitudinal growth curve for each 
fetus.
Nine hundred ultrasound measurements of fetuses born to HIV-infected mothers 
were compared to a uninfected control group of 3000 cross-sectional 
measurements in 1200 uneventful pregnancies delivered at term during the same 
years in the same geographical area.
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(iv) Statistical analysis
All calculations were done in S-Plus2000. The LMS method developed by Cole 
and Green was used to obtain centiles for the reference data set (Pinehiro, 2000; 
Cole, 1992) Z-scores were calculated with respect to the standard from the 
reference data set for measurements relating to fetuses of infected mothers using 
linear interpolation on the centiles. Fitted linear mixed effects models to the z- 
scores were used as a function of gestational age adjusting for birth weight, 
gestational age at delivery, CD4 count at delivery, gender, infection status of the 
child, and maternal antiretroviral treatment in order to assess the differences in 
fetal growth patterns between babies born to HIV-infected and uninfected mothers. 
Random effects for the intercept and the slope of gestational age for each fetus 
were included to allow for unobserved variables such as smoking or social 
background.
All reported t test values are two-tailed and univariate comparisons for categorized 
variables were tested with the x2 test.
7.2 Maternal characteristics and perinatal outcome
Baseline characteristics of 316 HIV-infected mothers are summarized in Table 7.1: 
127 (40%) women were not exposed to ART, 110 (35%) received Zidovudine 
(ZDV) prophylaxis and 79 (35%) combination therapy in order to reduce vertical 
transmission. Few women (15/189-8%) were on therapy before pregnancy and 
initiation of antiretroviral therapy in pregnancy was intended to prevent vertical 
transmission. Of the 174 women who started antiretroviral therapy during 
pregnancy, 109 (63%) received zidovudine monotherapy, and 65 (37%) double or 
triple therapy. Women treated during pregnancy with combination therapy were 
older on average than women who received no treatment (t= -4.164, p<.0.001) or 
who were on ZDV monotherapy (t= -2.81 p=.005).
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Virtually all women (308/316) were white Caucasian, seven were of African and 
one of other origin and overall 125 (39%) women had a history of illicit drug use 
(but were not current users), with a small percentage in the combination therapy 
group. Information on CD4 cell count was available for all women; 32 (10%) 
women were HIV symptomatic with a CD4 count less than 200 cells/ml. There 
were no significant differences between the three treatment groups in stage of HIV 
disease (X2= 6.13 p= 0.19), or CD4 cell count near the time of delivery (t= -0.09 
p=.92). Women who were not treated were more likely to report a previous history 
of IDU than treated women (X2= 38.54, p<0.001).
Elective caesarean section was the mode of delivery for 28% of the patients 
(33/127) in the no treatment group, for 59% (65/110) in the mono therapy group 
and for 86% (68/79) in the combination therapy group (X2= 73.44 p< 0.001); this 
trend reflects changing policies relating to the management of HIV-infected 
pregnant women over the period.
123
Table 7.1: Baseline characteristics of 316 HIV infected mothers by 
antiretroviral treatment
No therapy AZT Combination
Number of patients 127 110 79
Median maternal age (SD) 28.6±4.6 29.1 ±5.1 31.3±4.4
Ethnicity
Caucasian origin (%) 
African origin 
Others
123 (97%) 
3 
1
108(98%)
2
0
77(97%)
2
0
Mode of acquisition (%)
Past I DU 
Heterosexual risk 
Others
75 (59%) 
45 (35%) 
7 (6%)
34 (31%) 
72 (65%) 
4 (4% )
16 (20%) 
59 (74%) 
4 (6%)
Stage of disease (%)
Asymtomatic
Symtomatic and > 200 CD4 
Symtomatic and < 200 CD4
70 (55%) 
41 (32%) 
16 (13%)
66 (60%) 
35 (32%) 
9 ( 8%)
36 (46%) 
36 (46%) 
7 (8%)
Lymphocyte (cell/ml)
median CD4 (SD) 
median CD8 (SD)
490 (226) 
813(286)
466 (277) 
851 (350)
493 (228) 
846 (321)
Patients on therapy before 
pregnancy
— 1 (1%) 14(18%)
Gestational age at delivery 
(Median; range in weeks)
39; 29-42 38; 33-43 38;29-41
Birthweight (g) (Mean ±SD) 2998 (482) 2915 (466) 2990 (401)
Small for gestational age 
(< 10th percentile) **
16(12.5%) 13(12%) 9 (11.5%)
* classified as CDC classification **classified by clinicians according to a weight 
distribution, allowing for gestational age
There were no statistically significant differences in mean birth weight (t=1.3 9 
p=0.18) or mean gestational age at delivery (t=1.366 p=0.17) overall, but infants 
born to women who received combination treatment were on average delivered
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nearly one week earlier than those in the no treatment group (t=2.48, p=.0136 
Table 7.1).
The overall prematurity rate was 9%, higher in both the untreated (12%) and in the 
combination (13%) treatment group than in the group of women who received 
monotherapy only (6.4%), although the difference did not reach statistical 
significance (X2 =1.58 p=0.452). Only two cases of severe prematurity occurred at 
29 weeks of gestation. In the sub-set of 29 women with pre-term babies, there 
were no cases of small for gestational age , but in full-term deliveries, the 
association between maternal HIV and low birth weight was strong, although not 
statistically significant (OR 3.4, 95% Cl 0.57-5.6).
Fourteen of 79 (18%) patients on combination therapy discontinued therapy soon 
after their positive pregnancy test, and started antiretroviral again around 14 weeks 
of gestations, earlier than those who started ZDV therapy for the first time, around 
24 weeks in pregnancy (t=-8.648, p<0.001). There were a total of 6 maternal 
complications possibly associated with therapy, these included severe anaemia 
necessitating discontinuation of ZDV monotherapy at 32 weeks of gestation, 
thrombocytopenia at 36 weeks, hepatic cholestasis at 36 weeks, two emergency 
caesarean sections for placental abruptio at 33 and 37 weeks of gestation in the 
monotherapy treated group; and one case of placental abruptio at 29 weeks in a 
woman receiving combination therapy. No events were reported in the no 
treatment group.
Neonatal complications in infants of HIV-infected mothers who did not receive ART 
during pregnancy were rare and included one case of cerebral haemorrhage 
(caesarean section, birth-weight <2000 grams at 35 weeks of gestation, uninfected 
at follow-up) and one case of cardiac malformation (2/127-1,6% 95%CI 0.001- 
0.55). Among infants of the 110 infected women who received ZDV treatment
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during pregnancy there was one case of respiratory distress (emergency 
caesarean section at 36 weeks of gestation, birth weight 2185 grams), one case of 
kidney calicopielectasy dilatation, one case of syndactily and one case of agenesis 
of the external ear (4/110-3,6% 95%CI 0.009-0.9). No cases were reported in 
women on combination therapy.
A total of 33 children born to 316 infected mothers were diagnosed to be HIV- 
infected (overall 10.4%, 95% Cl 7.2-14.3); the rate of mother to child transmission 
was 24.4% (30/127, 95% Cl 16-31) in the untreated group, where the majority of 
these women delivered vaginally (68%), 2.7% (3/110 95% Cl 0.5-7.7) in the 
monotherapy group and zero (0/79 95% Cl 0-4.6) in the combination treatment 
group (X2 =39.79 p<0.001).
7.3 Intrauterine growth (z-score)
We used the 3000 measurements from 1200 uninfected women to construct the 
standards upon which the z-scores were based. Figure 7.1a to 7.1c show z- 
scores for head circumference (HC), abdominal circumference (AC) and femur 
length (FL) measurements adjusted by gender, maternal CD4 count and maternal 
treatment at delivery, and HIV-infection status of the child for all babies born to HIV 
mothers. Growth in all measures was significantly reduced (p<0.0001; p<0.001; 
p<0.001) in infants of HIV-infected mothers compared to the uninfected reference 
population, especially in the third trimester (slopes became negative around 30 
gestational weeks, indicating increasingly diverging lines). Intrauterine growth of 
children subsequently diagnosed to be HIV-infected did not differ significantly from 
those of uninfected infants (p=0.64). Type of maternal antiretroviral treatment was 
not significantly associated with a different pattern of growth among babies born to 
HIV-infected mothers (p=0.20).
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The average z-score of head circumference and femur length in HIV-infected 
women was substantially below the reference (-0.46 or 32th centile and -0.0997 or 
15th centile respectively), but the average z-score for abdominal circumference 
differed only marginally from that for the uninfected reference population (-0.023 or 
49th centile). To investigate within HIV-infected women the effect of maternal and 
HIV related variables we fitted a regression model, which included a random effect 
at mother level to allow for the effect on growth of unobserved variables such as 
smoking or social background. The inclusion of a random effect improved the fit of 
the model, but only marginally affected the magnitude of the associations of 
interest. Table 7.2 shows the coefficients for these variables and their p-values 
from a model including gestational age, gender, maternal ART and CD4 counts 
and infant’s infection status as well as a random effect. The negative coefficients 
for gestational age indicate that fetuses become smaller with respect to the 
standard as they near delivery, with the smallest effect for abdominal 
circumference. Maternal treatment did not show any association with intrauterine 
fetal growth, neither maternal CD4 did, probably due to the small sample size. 
(Figure 7.2)
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Figure 7.1(a): Fetal Head Circumference z-scores for babies born to HIV
infected mothers, by gestational age.
- p < 0.001
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(Empty Dots = individual z-score for each fetus with respect to the uninfected 
mothers’ standard. Continuous line = regression line for Z scores of HIV infected 
mothers allowing for repeated measurements.)
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Figure 7.1(b): Fetal Abdominal Circumference z-scores for babies born to
HIV-infected mothers by gestational age
p < 0.001
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(Empty Dots = individual z-score for each fetus with respect to the uninfected 
mothers’ standard. Continuous line = regression line for Z scores of HIV infected 
mothers allowing for repeated measurements.)
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Figure 7.1(c): Fetal Femur Length z-scores for babies born to HIV infected
mothers, by gestational age
p < 0.001
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(Empty Dots = individual z-score for each fetus with respect to the uninfected 
mothers’ standard. Continuous line = regression line for Z scores of HIV infected 
mothers allowing for repeated measurements.)
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Table 7.2: Association between Z-scores of fetuses of HIV infected mothers and 
selected maternal or infant variables; multivariable analysis, including random 
effect to allow for unobserved variables
Head
Circumference 
Coeff (p)
Abdominal 
Circumference 
Coeff (p)
Femur Length 
Coeff (p)
Gestational age (wks) -0.05 (p<.0001) -0.02 (p<.0022) -0.03 (p<.0001)
Gender 0.27 (p=0.08) 0.18 (p=0.17) 0.28 (p=0.32)
Congenital HIV Infection -0.17 (p=0.68) 0.45 (p=0.22) 0.22 (0.54)
Maternal Treatment 0.15 (p=0.39) -0.13 (p=0.41) -0.22 (p=0.16)
Maternal CD4 -0.28 (p=0.39) -0.15 (p=0.60) 0.23 (p=0.41)
Figure 7.2 Head Circumference for all babies born to HIV infected mothers 
stratified for maternal treatment
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(Empty Dots = individual z-score for each fetus with respect to the uninfected 
mothers’ standard. Continuous line = regression line for Z scores of HIV infected 
mothers allowing for repeated measurements.)
131
7.4 Birth weight and duration of pregnancy
7.4.1 Methods
(i) Objective
To investigate further whether the birth weight of infants born to HIV-infected 
women differs from those born to HIV uninfected mothers allowing for gestational 
age. This is to understand whether preterm babies were appropriate for gestational 
age or whether there was evidence for restricted intrauterine growth and whether 
this varied by HAART exposure.
(ii) Study design and data source
Prospective cohort study. Data used came from the ongoing longitudinal ECS 
study.
(iii) Study population
The European Collaborative Study is an ongoing cohort study in which HIV- 
infected pregnant women were enrolled and their infants prospectively observed in 
accordance with standard clinical and laboratory protocols (Newell 2002). The 
European Collaborative Study was set up in 1985 and includes 29 centres in 10 
European countries Information collected included timing of initiation and type of 
antiretroviral treatment, maternal CD4 cell count and viral load, history of injection 
drug use, and other socio-demographic characteristics. Data on delivery and 
neonatal characteristics were recorded, including mode of delivery, sex, birth 
weight, gestational age. Infection status of the children was recorded according to 
standard protocol. Gestational age at delivery was defined as delivery before 34 
weeks of gestation; between 34-37 and after 37 weeks of gestation; gestational 
age was confirmed by ultrasonography, with data reported to the nearest 
completed week. Mean z scores for birth weight for 5968 babies were calculated 
allowing for gender of the baby, gestational age at delivery, maternal ART
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treatment and HIV infectious status of the children, compared to the British
standard.
(iv) Statistical Analyses
Data entry was performed using Access 2000 (Microsoft), and analyses were made 
using SAS statistical software, version 8.02 (SAS Institute). Z-scores for birth 
weight, with reference to the 1990 British Growth Standard were calculated using 
the Growth program excel add-in (version 1.12, Institute of Child Health, London, 
2002-3). Ordinary least squares (OLS) regression models were used to investigate 
the effect of maternal characteristics, and ART use during pregnancy on these z- 
scores (Weisberg, 1985).
Mean z scores for birth weight for 5968 babies were calculated allowing for gender 
of the baby, gestational age at delivery, maternal ART treatment and HIV 
infectious status of the children, compared to the British standard.
7.4.2 Z-scores for birthweight from the large ECS cohort (5968 babies)
A multivariable model using data from the ECS cohort (5968 mother-child pairs) 
and adjusting for maternal ART treatment I DU in pregnancy, infectious status of 
the infants and gestational category was created. (Table 7.3 )
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Table 7.3 Multivariable model: z-scores for birthweight from the large ECS 
cohort (5968 babies)
Coeff p-value Adjusted Coeff p-value
Intercept -0.20 <0.001
Use of IDU
None/ex-user -0.66 <0.01 0.0
Current user -0.49 <0.001 -0.41 <0.001
Infection status
Negative -0.27 <0.001 0.0
Positive -0.27 <0.001 -0.13 <0.01
Antenatal ART exposure:
None 0.48 <0.001 0.0
Mono 0.35 <0.001 0.20 <0.001
Dual therapy 0.42 <0.001 0.27 <0.001
HAART 0.43 <0.001 0.19 <0.001
Gestational age at delivery
<34 weeks 0.044 0.582 0.0
34 to 37 weeks -0.12 0.182 -0.168 0.05
>37 weeks -0.39 <0.001 -0.44 <0.001
Maternal IDU during pregnancy reduced z-score for birth weight to a significant 
extent (mean z-score for IDU users -0.55 (30th centile) and for non IDU users - 
0.0042 (49th) and future HIV infective status of the child affected only marginally 
the size at birth (mean z-score -0.022, 41th centile).
The mean z-score for an infant not exposed to antenatal ART or maternal IDU in 
utero was -0.63 (indicating that the birthweight of this infant lay between the 25th 
and 50th centile). Infant exposed to antenatal monotherapy or double therapy or 
HAART were heavier, with estimated mean z-scores respectively of of -0.156 (43th 
centile),-0.124 (45th centile) -0.07 (47th centile ) (Figure 7.3).
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Categorising gestational age at delivery into three main categories (less than 34 
week, between 34-37 weeks, and above 37 weeks), mean z-scores progressively 
decreased from -0.10 (46th centile), -0.13 (45th centile) and to -0.30 (37th centile) 
indicating that children born to HIV infected mothers when compared to their 
standard, become statistically different (smaller) towards the end of pregnancy 
(Figure 7.4), after controlling for maternal antiretroviral treatment and use of IDU 
during pregnancy.
Figure 7.3
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Figure 7.4
Box-plot for z-scores of birthweight by gestational age
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Z-score for birthweight at different levels of treatment and gestational age
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There was a significant joint effect of HAART and gestational age on birthweight (p 
value for the interaction terms 0.020) with the effect being concentrated on children 
born after 35 weeks of gestation with similar coefficients for the other variables 
included in the multivariable analyses than seen previously without inclusion of the 
interaction term.
The birthweight of babies born prematurely was more appropriate for gestational age 
than that of infants born at term, suggesting that babies in utero tend to slow their 
growth pattern proportionally with their gestational age. (Figure 7.5)
This would lead to the conclusions that premature delivery when occurring in HAART 
treated women is likely to be due to somehow toxicity on the fetal membranes and not 
due to fetal distress.
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7.5 Key points
• Growth was significantly reduced (p<0.0001; p<0.001; p<0.001) in infants of 
HIV-infected mothers compared to the uninfected reference population, 
especially in the third trimester (slopes became negative around 30 
gestational weeks, based on Z- scores for head circumference (HC), 
abdominal circumference (AC) and femur length (FL) measurements adjusted 
by gender, maternal CD4 count and maternal treatment at delivery.
• The average z-score of head circumference and femur length in HIV-infected 
women was substantially below the reference (-0.46-32th centile and -0.0997- 
15th centile respectively), but the average z-score for abdominal 
circumference differed only marginally from that for the uninfected reference 
population (-0.023-49th centile).
• Maternal treatment did not show any association with intrauterine fetal growth, 
neither maternal CD4 did, probably due to the small sample size.
• Comparing birthweight of babies born to HIV infected mothers to the British 
Standard, categorising gestational age at delivery mean z-scores 
progressively decreases indicating that children born to HIV infected mothers 
when compared to their standard, become statistically different (smaller) 
towards the end of pregnancy.
• Infant exposed to antenatal monotherapy or double therapy or HAART were 
heavier.
• Babies born prematurely are more appropriate for gestational age, 
suggesting that babies in utero tend to slow their growth pattern proportionally 
with their gestational age.
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Chapter 8 Maternal post partum complications in relation to mode of 
delivery
SummarvT o inform the debate on the use of elective caesarean section (CS) 
delivery in HIV-infected women, we investigated the occurrence of clinical events in 
the immediate post-partum period in women delivering in 13 European centres. We 
analysed data from two matched-case-controls studies (HIV infected women 
matched to HIV uninfected women) on spontaneous deliveries and elective 
caesarean section.
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8.1 Methods
(i) Objectives
To determine whether the surgery involved in delivery by elective caesarean 
section is related to post-partum complications in HIV-infected mothers.
(ii) Study design and data sources
Two case-control studies, one for vaginal delivery and one for caesarean section, 
HIV-infected women (cases) were matched with HIV-uninfected controls. HIV infected 
women were enrolled in the ECS longitudinal study. Clinicians were asked, where 
possible, to collect extra data on post partum complications. Sample size to detect 
the clinically important difference (at 5%  level; 95%CI) between the two 
groups was calculated using Epinfo program for case-control studies. 
Assumptions for this calculation included random sampling from the 
population and a doubling of the rate of complications in the HIV infected 
group (OR= 2) with 80% power.
(iii) Study Population
Data on HIV-infected women delivering in one of 13 European HIV reference centres 
in Italy, Spain, Sweden, Poland and Ukraine from 1992 to 2002 were collected 
retrospectively from the medical notes.(Appendix III) Most of these sites were already 
participating in the European Collaborative Study. Local ethics permission was 
obtained.
In a case-control approach involving two studies, one for vaginal delivery and one for 
caesarean section, HIV-infected women were matched with HIV-uninfected controls. 
Controls were selected as the first uninfected woman delivering after the index case 
on the birth register of the same unit, without a history of current injecting drug abuse. 
Cases and controls were matched by age, ethnicity and parity, for being admitted to 
the delivery unit with active labour in the spontaneous delivery arm, or for having
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received antibiotics during labour or during caesarean section. Women admitted for 
medical induction of labour or for emergency caesarean section were not included in 
the study. (NIH, 1981; Watts, 2000) Post-partum haemorrhage requiring blood 
transfusion or surgical treatment, pneumonia or pleural effusion, peritonitis, sepsis, 
diffuse intravascular coagulation and thromboembolism were considered major 
complications. Anaemia not requiring transfusion (less than 10g%), fever in excess of 
38°C after twenty four hours from delivery, wound infection, curettage of the uterine 
cavity, endometritis and urinary tract infection were considered minor complications.
Recorded clinical parameters for HIV infection included CD4 lymphocyte count in late 
pregnancy, use of antiretroviral therapy, and clinical symptoms. Routine 
measurements of HIV RNA viral load in HIV-infected women was only introduced in 
these centres in recent years and this information was thus not available for the 
majority of cases.
(iv) Statistical analysis
Statistical significance of differences between means was evaluated by Student’s t 
test, differences between proportions were evaluated by %2 test in HIV-infected 
women and uninfected women separately. The analysis of post-partum 
complications and HIV infection used conditional logistic regression analysis for the 
two different matched case-control studies: (a) vaginal delivery, and (b) caesarean 
section. All analyses were carried out using a commercial software package 
(STATA 7).
8.2 Clinical characteristics
A total of 250 matched pairs were delivered vaginally and 158 by elective caesarean 
section. Table 8.1 shows baseline characteristics of HIV-infected and -uninfected 
women by mode of delivery and the prevalence of post-partum complications in the
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four groups. The overall complication rate was 29.2% (119/408) among HIV-infected 
women and 19.3% (79/408) for the HIV-uninfected group (OR 1.7, 95% Cl 1.22-2.40, 
p=.0001). Among the 316 women delivered by caesarean section, 42.7% (135) 
experienced complications, as did 12.7% (63) of the 500 women who delivered 
vaginally (OR 5.1, 95% Cl 3.6-7.42, p=.001).
Within mode of delivery group, infected and uninfected women did not differ 
significantly in terms of age, height, birth weight or neonatal outcome. Hospital stay 
was longer for mothers delivered by caesarean section, regardless of infection status 
(Table 8.1). Maternal weight at delivery for HIV-uninfected mothers was higher for 
those who delivered by caesarean section compared with those in the vaginal 
delivery group.
Amongst the HIV-infected women, those in the caesarean section arm were more 
likely to be on antiretroviral therapy (ART) during pregnancy (44 (27.8%) not treated, 
28 (17.7%) on monotherapy and 86 (54.4%) on combination therapy) than those in 
the vaginal arm (44 (17.6%) on monotherapy, 206 (82.4%) not treated) (p<0.001) 
reflecting the time periods these women delivered in, and changes in clinical 
management of HIV-infected pregnant women. Only a small proportion of infected 
women in both arms were severely immunosuppressed with a CD4 cell count of less 
than 200 cells per ml: 18/250 (7.2%) in the vaginal arm and 21/158 (13.3%) in the 
caesarean arm (p=0.1).
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Table 8.1: Maternal characteristics according to HIV infection and prevalence of post-partum complications by mode of delivery
HIV-infected women HIV-uninfected women
Number: 816 Vaginal 
delivery (250)
Caesarean 
section (158)
P value Vaginal delivery 
(250)
Caesarean 
section (158)
P value
Age yrs (mean, SD) 26.71 (3.95) 29.00 (6.944) 0.60 25.89 (3.6) 29.6 (7.8) < 0.001
Weight kg (mean, SD) 67.85(11.44) 65.8(10.52) 0.90 63.23 (9.3) 72.00 (12.93) < 0.001
Height cm (mean, SD) 164.80 (7.19) 163.90 (7.40) 0.98 163.55 (6.8) 162.66 (7.3) 0.10
Gestational age in weeks 
(mean, SD)
38(1.6) 37.88(1.39) 0.97 39 (1.2) 38.54(1.5) < 0.001
Blood loss >500 ml n (%) 6 (2.43) 44 (28.35) OR=15 (6-42) 8 (3.2) 36 (23.0) OR=8.93 (3.8-21)
Minor complications n (%)
Yes
No
42 (16.8) 
208 (83.2)
77(48.7) 
81 (51.3)
OR= 0.34 
(0.25-0.47)
21(8.4)
229(91.6)
58 (36.7) 
100 (63.3)
OR=0.239
(0.14-0.36)
Major complications n (%)
Yes
No
0
250 (100)
5 (3.2)
153 (96.1)
OR= 8.4 
(0.92-18.2)
0
250 (100)
1(1)
157 (99) NA
Mean hospital stay (days) 
(SD)
5.4 (3.3) 7.4 (3.7) < 0.001 5.3 (3.2) 8.7 (5.9) < 0.001
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8.3 Complications after vaginal delivery
The following analyses refer to the 250 matched pairs delivered vaginally. All women 
delivered between the 37th and the 41st week of gestation. In 183 (73.2%) pairs 
membranes were intact when admitted to the delivery unit; while in the remaining 67 
(26.8%) pairs the membranes were ruptured at admission (for 35 pairs for more than 
12 hours). Eight (3%) pairs received Amoxicillin 2 gram intramuscularly as 
prophylaxis for bacterial infection. Episiotomy was performed in 147 pairs (in 92 as a 
mediolateral and in 55 as a median perineal incision). Only three uninfected patients 
required manual removal of the placenta.
There were no major complications in this group of either HIV-infected or in 
uninfected women. In matched analysis post-partum fever was the only minor 
complication for which HIV-infected women were at significantly higher risk compared 
to uninfected women (OR 4.5, 95% Cl 1.55-13.07, p=.001). Table 8.2 shows the 
correlation between fever and episotomy in the two groups of women. Although there 
was a trend towards increased risk of endometritis in infected women, this did not 
reach statistical significance (OR 4.4, 95% Cl 0.44-12 p=0.3). In multivariate analysis 
to assess the effect of selected risk factors on the incidence of complications in these 
infected women, including history of illicit drug use, CD4 lymphocyte count, 
episiotomy, only episiotomy, and in particular a medio-lateral incision (p=0.022), was 
associated with a significant increase of puerperal fever [z=- 3.19 (SE 0.312 
P>z=0.001 (95% Cl -1.61 -0.38)
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Table 8.2 Fever and episiotomy
HIV-positive
Mothers
HIV-negative
mothers
P value
Median episiotomy 4/55 1/55 Ns
Mediolateral episiotomy 9/92 1/92 0.02 (OR 9.8)
No episiotomy 5/63 2/63 Ns
8.4 Complications after caesarean section delivery
All 158 matched pairs in this group were delivered between the 37th and the 39th 
week of gestation, all had intact membranes when admitted to the hospital and none 
were in labour. All pairs received prophylactic antibiotics during the surgical 
procedure. Median duration of the procedure was 45 minutes (min 22 - max 90) and 
a total of 26 women (16%) were assisted by a senior surgeon (consultant or head of 
department) at delivery. Clinical indications for caesarean section delivery included 
reduction of vertical transmission for all infected cases and for the uninfected controls: 
breech presentation (73), macrosomia (19), maternal hepatitis C infection (8), 
maternal human papillomavirus infection (5), maternal HELLP syndrome (10), uterine 
abnormalities (26), obesity (7) and choice (10). Wound drainage was used once in 
four HIV-infected and two uninfected women for less than 3 days and a bladder 
catheter was used for less than 24 hours in 201 (80%) patients: 85 (42%) cases and 
116 (57%) controls. The method of caesarean section was reported as conventional 
for all patients and spinal anaesthesia was used in 13% (32) of the HIV-infected 
cases.
There were five major complications in the HIV-infected cases and only one among 
the controls (Table 8.2). All five HIV-infected cases with major complications were on 
ART during pregnancy. Overall, infected women were at higher risk of both minor
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(OR 1.51, 95% Cl 1.22-2.41, p=.001) and major complications (OR 5.1, 95% Cl 0.58- 
45.0) compared with uninfected women. Anaemia not requiring blood transfusion 
was the most prevalent complication regardless of infection status but was 
significantly more frequent in the infected cases [z=- 2.18 (SE 0.27) P>z=0.029 (95% 
Cl -1.1 -0.6)]. With the exception of anaemia there were no significant differences 
between cases and controls in relation to minor complications [z=- 1.1 (SE 0.83) 
P>z=0.273 (95% Cl -2 .55  -0.72)].
Among anaemic HIV-infected women there was a strong association between 
excessive blood loss during surgery and post-partum anaemia (OR=2.7, 95% Cl 1.47 
- 4.9), irrespective of the seniority of the surgeon. Anaemia was strongly associated 
with both the use of antiretroviral therapy during pregnancy (OR=3.1, 95% Cl 2.7-6.9), 
and a low CD4 count (OR=2.9, 95% Cl 2.1-9.1).
Table 8.3: Post-partum complications, by mode of delivery and infection status
Vaginal delivery 
250 matched pairs
Caesarean section 
158 matched pairs
HIV infected 
250
HIV uninfected 
250
HIV infected 
158
HIV uninfected 
158
Minor complications
Fever > 38° 18 3 4
Anaemia not requiring 
transfusion
7 6 64 49
Urinary tract infections 3 3 4 1
Endometritis 11 5 2 4
Haematoma 1 1 0 0
Wound gapping 1 1 3 0
Wound infection 1 1 1 0
Total 4 2 * 2 1 * 77A 58A
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Table 8.3: Post-partum complications, by mode of delivery and infection status
Major complications
Peritonitis 0 0 3 1
Pneumonia 0 0 2 0
Sepsis 0 0 0 0
Thrombosis 0 0 0 0
Diffuse intravascular 
dissemination
0 0 0 0
Subileus/ileus 0 0 0 0
Haemorrhage 0 0 0 0
Total 0 0 5 1
8.5 Conclusions
Table 8.3 shows complications after delivery according to infectious status of the 
mother and mode of delivery. Results indicate that fever was a recurrent post-partum 
complication for those women who delivered vaginally and anaemia for those who 
delivered by caesarean section. Overall HIV-infected women suffered an increased 
risk of minor complications. Major complications were more likely to occur in the 
caesarean arm than in the vaginal delivery arm
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8.6 Key points
•  Two separate matched case-control studies (vaginal and elective CS 
deliveries) among infected women (cases) and uninfected controls 
delivering between 1992 and 2002.
• The prevalence of minor and major post-partum complications was 
assessed overall for infected and uninfected women; within mode of 
delivery group (vaginal/cesarean section) the complication rates of infected 
cases were compared with uninfected controls in a matched analysis.
• Overall complication rates were 29.2% (119 of 408) for HIV-infected 
women, 19.4% (79 of 408) for uninfected women, 42.7% (135 of 316) for 
CS deliveries and 12.6% (63 of 500) for vaginal deliveries.
• There were no major complications in women delivering vaginally; but, 
compared with controls, HIV-infected women were at increased risk of 
puerperal fever [odds ratio (OR), 4.5; 95% confidence interval (Cl), 1.55- 
13.07), especially after medio-lateral episiotomy.
• In the CS group, there were six major complications (five among cases, one 
control) (OR, 5.1; 95% Cl, 0.58-45) and cases had an increased risk of 
minor complications (OR, 1.51; 95% Cl, 1.22-2.41) compared with controls, 
mainly anaemia not requiring blood transfusion
• HIV-infected pregnant women are at increased risk of post-partum 
complications regardless of mode of delivery
• Modification of clinical practice, particularly use of prophylactic antibiotics, 
would reduce this risk.
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Chapter 9 Childbearing in HIV infected women 
(discussion and recommendations)
Europe
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9.1 Introduction
The era of combination therapy with highly active drugs has resulted in HIV 
infected individuals living longer and healthier lives (Mocroft 2003; Vittinghoff
1999). HIV infection is now classified as a chronic disease in the Western world 
because of a significant increase in the quality and expectancy of life with the 
introduction of highly active antiretroviral therapy. This, along with the 
developments in preventing vertical transmission and partner infection, has made it 
necessary to open the discussion on the reproductive desires and rights of HIV 
infected individuals and to provide clinicians involved in their care with 
recommendations.
The studies presented in this thesis focused on HIV-infected women’s reproductive 
and sexual health as assessed by themselves as well as the wider impact of HIV 
and treatment on their reproductive choices and pregnancy outcomes. Analysis of 
data from several cross-sectional and longitudinal studies on reproductive 
outcomes of HIV infected women was preceded by a cross-sectional survey of 
reproductive choices in relation to relationships, their partners, desire of 
parenthood and previous obstetric experience. Results from the reported studies 
explore three different aspects of reproductive behaviour in HIV infected women, 
confirming a strong desire for motherhood, suggesting a small interaction between 
HIV and fecundability and highlighting the importance of pregnancy management.
The studies reported here complement each other and provide further evidence to 
inform guidelines and recommendations on the management of HIV infected 
childbearing women in Europe.
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9.2 Reproductive choices
Most studies examining the impact of HIV and antiretroviral treatment on desire of 
parenthood and reproductive choices have been on a population rather than an 
individual basis (Gray 1998; Degrees 1997; Forquet 2001). To date, little has been 
discussed in the literature regarding the various factors that could influence the 
reproductive options of HIV-infected women.
Reproductive decision making in women infected with HIV is likely to be influenced 
by a complex array of factors, including demographic and situational variables, 
psychological patterns, locus of decision making, counselling techniques, access to 
care, and the attitude of health care providers.
Previous studies have been limited to discussing the decision of whether or not to 
become pregnant and to describing women feeling in relation to this. (Wesley, 
1996). Three major themes emerged from an American survey on 25 HIV infected 
women: (1) motherhood was viewed as a joy and a means of meeting a woman’s 
own needs, (2) concerns about their children's well-being, and (3) the minor role 
that HIV infection played in their lives. Women reported negative reactions to 
providers who focused exclusively on their HIV status, and not on the need to view 
the women's lives as a whole. (Wesley, 1996)
A similar suggestion of the importance of culture over HIV infection came from a 
European study, in which the incidence of pregnancy and terminations after HIV 
diagnosis were three times lower in white European than in women of African 
origin, (van Benthem 2000)
It is likely that far more HIV infected women in Europe are now considering to 
become pregnant, although a London-based study, published in 1996, comparing 
rates of reproductive events before and after HIV diagnosis in a cohort of women 
with HIV infection, concluded that diagnosis of HIV infection in women had a
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substantial impact in reducing live-birth rates (women aged 20-34 years, the age- 
adjusted live-birth rate fell by 44% , reflecting an increase in termination rate). 
(Stephenson, AIDS 1996)
However, since that time, HAART has became widely available and interventions 
to reduce mother to child transmission have proven to be effective. Results from 
the survey reported in this thesis indicate that desire of parenthood was associated 
to maternal well being as having no HIV symptoms and the knowledge that the risk 
of mother to child transmission can be decreased with appropriate interventions. 
Pregnancies were more likely to occur in women with no previous livebirths and in 
those in a long standing relationship with an uninfected partner.
These findings are in line with results from a large survey conducted in America 
including 1,421 HIV-infected adults who were part of the HIV Cost and Services 
Utilization Study focusing on fertility desires and intentions of HIV infected men and 
women (Chen 2001). HIV-positive individuals who desired children or expected 
children were reported to be younger, to have fewer children and to report higher 
ratings of physical functioning or overall health than their counterparts who did not 
desire children. Women whose partner's HIV status was known were significantly 
less likely to desire children but were significantly more likely to expect children in 
the future than were women whose partner's HIV status was unknown (Chen, 
2001).
Regardless of women's pregnancy experiences or intentions, reproductive 
decision-making themes in the survey presented here included: the perceived risk 
of vertical transmission; beliefs about vertical transmission risk reduction strategies, 
desire for motherhood, the HIV infection status of their partners, attitudes of health 
care providers; and the impact of the mother's health and longevity on the child.
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Desire for children was higher among HIV discordant couples where the male was 
uninfected, thereby suggesting that the HIV status of the male partner is an 
important determinant to a couple’s reproductive practice, as important as the 
health condition of the woman.
Women who reported not to want any children after their diagnosis did not mention 
vertical transmission risk as the reason, and most of these women already had 
children or were not in a relationship. Those who became pregnant or desired 
children after their diagnosis seemed more confident in the efficacy of risk 
reduction strategies and often did not already have children.
Women who wanted children or were pregnant, were more likely to have a long­
standing relationship, be married or cohabiting, were heterosexually infected and 
older than non-pregnant HIV women. Time taken to conceive suggested that 
overall, conception was not a problem for most women and prevention of viral 
transmission from an infected woman to an uninfected man relied often on timed 
self-insemination using quills. A number of women failed to conceive, needing 
fertility advice and treatment as one or both may have impaired fertility, although 
fertility remains a medical concept related to both partners, and comparison with 
normal rates is difficult as most of the available data are on birth rates in 
populations (Thackway 1997).
These data, confirm previous findings on couples infected with HIV and their 
reproductive needs. Couples infected with HIV are actively seeking reproductive 
assistance for different reasons depending on which partner is infected and which 
has a fertility problem. When the woman is HIV infected or both the partners are, 
they are likely to need help when they fail to conceive spontaneously or by self 
insemination.
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The issue of reproductive care in HIV infected individuals still poses ethical 
dilemmas and practical implications for the couples and the carers. In couples who 
have already tried to conceive unsuccessfully, medical intervention permits the 
conception of a child who is at risk of acquiring HIV, even with optimal reproductive 
care. It can be debated whether the couple’s desire to have a child justifies medical 
intervention that involves the potential risk of infection for the the child.
In the past few years a number of clinics in several European countries have 
started to offer reproductive services for couples with HIV infection (AE SEmprini 
Personal Comunication 2005 on Creathe Network-Centers for Reproductive 
Assistance To HIV couples in Europe), although methods and procedures for 
reproductive counselling or fertility care are not yet standardised.
The impact of living with HIV can be observed in the awareness of the couple and 
their adoption of safer sexual practices. Both the pregnant and non-pregnant 
women in the survey reported to use condoms regularly, although condom use was 
higher in serodiscordant couples. Sexually transmitted infections were reported to 
be recurrent gynaecological problem. This confirms results from a large French 
study (Heard 2004) and emphasizes that reproductive counselling is very important 
and should include a discussion on reproductive issues, HIV and other sexually 
transmitted infections in relation to the partner's HIV infection status.
Although this is a cross-sectional survey and could not take into account changes 
in management over past few years, results suggest that in these days knowledge 
of HIV infection does not influence the desire for children or the decision regarding 
pregnancy in HIV-infected women living in Europe .
The fact that many HIV-infected adults desire and expect to have children has 
important implications for the prevention of vertical and heterosexual transmission 
of HIV, the need for counselling to facilitate informed decision-making about
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childbearing. The availability of treatment and improvement in the quality of life, 
have given women living with HIV greater autonomy with respect to reproductive 
choices.
The second part of this study focused on reproductive outcomes and specifically on 
the interaction between antiretroviral therapy and pregnancy duration, intrauterine 
fetal growth and neonatal birthweight and post partum complications
9.3 Immunology of HIV and outcome of pregnancy
HIV disease and pregnancy both stimulate a Type 2 cytokine response and inhibit 
the production of Type 1 cytokines. The present study has focused on the 
secretion of Type 1 (IL-2) and Type 2 (IL-10) cytokines by peripheral blood 
lymphocytes over the course of pregnancy, to understand the association between 
HAART exposure and risk of premature delivery in HIV infected women (ECS
2000). We report decreasing levels of IL-10 (Type 2) between the beginning and 
the end of pregnancy, especially evident after HIV-specific stimulation, in HAART 
treated women delivering prematurely and a dominant significant effect of Type 1 
(IL-2) cytokines on the risk of premature delivery. Results also suggest that the 
effect of HAART on the risk of prematurity is mediated through its effect on the 
cytokine environment, rather than through a direct toxic effect on the fetus or 
placenta.
An association between modulation of cytokine production and the likelihood to 
deliver healthy newborns at term has been shown in a number of studies (Marzi 
1996; Raghupaty 1997). Increased Type 1 cytokine responses are seen in women 
with recurrent pregnancy losses and in pre-eclamptic patients. In successful 
pregnancies the maternal-fetal interface shows a higher expression of B7-H1, a 
costimulatory molecule associated with IL-10 production (Trabattoni 2003). In our 
population of HIV infected pregnant women delivering prematurely, trends of IL-10
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and IL-2 were highly negatively correlated. In logistic regression, levels of non- 
specifically (pha) stimulated IL-2 was most strongly associated with the risk of 
premature delivery, while the effect of HAART was indirectly captured by the 
decrease in HIV specific (env) stimulated IL-10 slopes. IL-10 levels (Type 2) were 
consistently higher in the women delivering at term than in those delivering before 
37 weeks, but the effect of IL-10 was not statistically significant in multivariate 
analyses, suggesting a secondary role of IL-10 in the mechanism of premature 
delivery, dependent on HAART and its link with IL-2.
While the bioactivity of different cytokines may not be quantitatively equivalent with 
considerably higher levels of IL-10 than of IL-2, the concentrations of these 
cytokines relative to each other are of importance because of the mutually 
inhibitory effects of Type 1 and Type 2 activity and therefore it is important to 
analyse the whole environment.
Although results are in agreement with the hypothesis that the association between 
HAART and increased risk of premature delivery is mediated by the changes in 
cytokine environment, the limited number of women in this study precluded further 
investigations and it was not possible to investigate whether different antiretroviral 
compounds (for example PI versus NNRTI) affect the duration of pregnancy in 
different ways, reflecting a possible different immuno modulating effect. Research 
is ongoing to investigate whether the effect is seen in local tissues like amniotic 
membranes or the decidual interface, in which immune cytokines may play an 
important role in the pre-apoptotic activation even when not secreted by circulating 
immune cells.
These preliminary data indicate the underlying mechanism for premature delivery 
in HIV HAART treated women, and highlight the need for careful consideration 
when initiating immunomodulating compounds during or before pregnancy.
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9.4 Intrauterine fetal growth, duration of pregnancy and birth weight
There is lack of evidence to substantiate the suggestion that exposure to maternal 
HIV infection during fetal life may affect growth. Growth patterns in uninfected 
children who are born to mothers with HIV-1 infection have been described in detail 
previously beyond early childhood (European Collaborative Study 2003).
However, although poor growth and low birth weight have been reported in HIV- 
infected children, it is unclear what happens before birth and whether growth 
faltering is an independent HIV-related symptom or caused indirectly. To further 
investigate the effect of HIV and its treatment on the fetal environment, we 
analysed intrauterine growth of fetuses born to HIV-infected mothers as determined 
by head, abdomen circumference and femur length.
Results were based on data of HIV infected mothers delivering after 1990, and the 
changing epidemiological features of the HIV infected pregnant population during 
the past decade were reflected in the changes over time in use of antiretroviral 
therapy, mode of delivery and maternal mode of acquisition.
The intrauterine growth of fetuses born to HIV infected mothers as determined by 
head and abdomen circumference, was significantly reduced compared to that of 
fetuses born to HIV uninfected mothers.
Fetal growth was consistently lower in HIV infection than in normal controls 
obtained from the same population. Absence of skewness of birth weight, 
associated with the intrauterine growth curves, would confirm a genuine biological 
result.
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To better understand the pattern of growth in children born to HIV infected mothers, 
this study also analysed size at birth (birthweight) of babies born to mothers 
enrolled in the same large prospective European cohort (ECS) and compared to 
the British standard (Cole, 1996).
Birthweight of babies born prematurely was more appropriate for gestational age 
than that of infants born at term, suggesting that babies in utero tend to slow their 
growth pattern proportionally with gestational age. Children who were premature 
following HAART exposure were heavier than those who were premature due to 
other causes, suggesting that premature delivery occurring in HAART treated 
women may be due to increasing toxicity on the fetal membranes and not due to 
fetal distress.
The damage to growth in fetal life was independent from the HIV infection status of 
the infant. The increased prematurity rate in infected women treated with 
combination ART has been noted before, and is probably related to labour initiation 
rather than fetal distress according to their appropriate birth weight for their 
gestational age. It is speculative to suggest that HIV infection can impair the 
prenatal environment, possibly through damage to placental cells and function and 
this progresses with time, affecting more intrauterine growth of full term babies. 
HAART can damage prenatal environment altering the cytokine balance and 
probably impacting on amniotic membranes, causing indirectly their rupture.
Our findings complement those from African studies, in which infants born to HIV- 
infected mothers have been shown to be of lower birth weight than those of HIV- 
uninfected mothers in providing for the first time evidence of impaired in utero 
growth in infants born to HIV-infected mothers that seems to be determined more 
by maternal HIV infection than by maternal antiretroviral therapy. (Arpadi 2000; 
Markson 1996).
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Improved prenatal care could be offered to this women as it may offer protection 
against perinatal morbidity and mortality due to low-birth weight, although as 
Samuel Shwartz noted in 1932 "the role of prenatal care in the incidence of 
prematurity and perinatal mortality is neither well defined nor well established" 
(Shwartz 1932).
The cause of growth failure remains unknown and additional studies are needed to 
assess the possible interaction between maternal HIV infection and placental 
function. This study provides further insight on the interaction between HIV 
infection and pregnancy and completes one of the very few model of growth in the 
literature.
9.5 Maternal post partum complications in relation to mode of delivery
The aim of this project was to provide information on the comparative risks of
complications associated with HIV infection and mode of delivery, to help inform 
decision-making by clinicians and women.
The overall prevalence of any post-partum complication here was five-fold higher in 
the caesarean section than in the vaginal delivery group, irrespective of HIV 
infection. However, most complications were minor, relating to anaemia and fever, 
with serious complications limited to women delivered by caesarean section. 
Consistent with previous reports, we found an increased risk of minor 
complications after elective caesarean section in infected women, albeit of a lesser 
magnitude (Semprini 1995, Marcollet 2002; Rodriguez 2001), but we also show 
increased risk after spontaneous vaginal delivery.
In previous studies among infected women, post-partum fever was associated with 
elective cesarean section delivery and immunosuppression. However, prevalence 
of fever was similar in infected and uninfected women delivered by electice 
caesarean section here; infected women were more likely to be on ART for long
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periods, with restored immune function, and were also exposed to routine antibiotic 
prophylaxis. The infrequent use of antibiotic prophylaxis may partly explain the 
finding here that fever was common among infected women delivering vaginally. 
The association found between fever and medio-lateral episiotomy is not surprising 
given the extensive muscular and vascular damage associated with this procedure. 
Any delivery, but particularly abdominal delivery, results in blood loss, and a 
subsequent physiological fall in haemoglobin. In HIV-infected women, anaemia 
was also associated with ART use. Prevention of MTCT relies on the combination 
of elective caesarean section and antiretroviral prophylaxis, both of which are 
associated with anaemia (Newell 2002)
Women should participate in decisions regarding mode of delivery and be informed 
of potential risks and benefits. However, infected women opting for vaginal delivery 
should be informed of the 8-10% chance of needing an emergency caesarean 
section due to labour complications. This might expose the child to an increased 
MTCT risk and the mother to complications.
Paradoxically, infected women at greater theoretical risk of complications following 
caesarean section delivery, i.e. those with advanced disease, are also those who 
would benefit most regarding prevention of MTCT. Although antenatal HAART use 
is associated with a substantial decline in MTCT, elective caesarean section 
remains an independent intervention. Furthermore, it has been shown that elective 
caesarean section is cost-effective even when the MTCT rate among vaginal 
deliveries is low (ECS 2001).
A strategy of elective caesarean section for HIV-infected women in Europe does 
not appear to increase risk of serious maternal morbidity while it should be noted 
that vaginal delivery in infected women is also not risk-free. Results suggest the 
need to adopt precautions to reduce risk of infection after vaginal delivery
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specifically for infected women, and of anaemia after caesarean section generally. 
HIV-infected women delivering vaginally requiring a medio-lateral episiotomy might 
benefit from antibiotic prophylaxis, which are already the standard of care during 
caesarean section procedures. Reducing risk of anaemia after caesarean delivery 
can be achieved by prenatal iron supplementation and by spinal rather than 
general anaesthesia (Andrews 92; Avidan 2002). Spinal anaesthesia, increasingly 
used, is associated with reduced blood loss and additionally reduces risk of post- 
surgical pneumonia.
9.6 Limitations and suggestions for future research
Mother to child transmission can be substantially reduced with maternal 
antiretroviral treatment and elective caesarean section. Whether there is benefit of 
elective caesarean section delivery in women who receive HAART is still debated, 
although it is shown that vaginal delivery is also not risk free in terms of post natal 
complications and increased risk of vertical transmission. Similarly, HAART use 
has been associated with premature birth and the understanding of the underlying 
mechanism in relation to intrauterine growth and birth weight of these children 
could the inform obstetric management and therapeutic options.
The majority of data presented are based on observational data and this remains a 
major limitation. Bias, like chance and confounding should always be considered 
as a possible alternative explanation of any observed statistical association, 
although this has always been taken into account in the analyses through the use 
of appropriate statistical methods, study design and conduct.
A limitation of the survey of HIV infected women was the potential for selection bias 
as subjects had more contact with an Obstetric and Gynaecological Unit, and thus 
they may be better informed, and a selected group
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To strengthen work on cytokines it would have been helpful to investigate two 
important other Type 1 and type 2 cytokines, IFN-gamma and IL-4, particularly with 
respect to the mutually inhibitory effects of Type 1 and Type 2 activity, which are 
mainly exerted by IFN-gamma and IL4. But the cost of laboratory test forced us to 
choose only II-2 and 11-10.
Future research could address the issue of HAART induced immunologic aspects 
of premature delivery, such as apoptosis in premature rupture of fetal membranes 
and the roles of cytokines in inducing the pre-apoptotic pathway, as a result of the 
use of antiretroviral treatment. Further research is needed in the area of placental 
functioning and HIV as suggested by the work on intrauterine growth and birth 
weight in newborn babies born to HIV infected mothers .
In summary, proposed components of a service for HIV infected women in Europe 
include the following:
(a) Reproductive counselling
Done on a routine basis should include a discussion on reproductive issues, HIV 
and other sexually transmitted infections, partner HIV infection status.
Access to fertility advice and treatment should be easy to all couples infected with 
HIV; access to gynecologic and obstetric care, should be integrated into both AIDS 
clinics and drug treatment programs.
Although the use of contraception among HIV infected women was not an objective 
of this thesis, the literature review highlighted that despite significant advances in 
the development of new contraceptive technologies ( ie transition from high-dose to 
low-dose combined oral contraceptives, from inert to copper- and levonorgestrel- 
releasing vaginal lUDs, combined injectable contraceptives, a combined hormonal 
patch and ring, progestogen-only injectables and implants) current policies and
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health care practices within the HIV infected population are largely based on small, 
mostly unpublished studies (WHO, 2004). There is, thus, a need for more 
conclusive data on the safety and efficacy of contraceptive use in HIV-infected 
women, possible interactions with antiretroviral therapy, as well as data that 
describe the effects of patient education and counselling and closer follow-up on 
effective long-term contraception in HIV-infected women.
Prenatal counselling should be multidisciplinary, involving the infectious disease 
specialist and the obstetrician together at an earlier stage.
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(b) Pregnancy
Need for intrauterine growth longitudinal evaluation, although the magnitude of 
growth failure remains small, as prenatal care can impact on weight at birth and on 
duration of pregnancy, reducing the morbidity and mortality risks.
Need for careful consideration when using immunomodulating compounds during 
pregnancy, in relation to the risk of premature delivery.
Spontaneous vaginal delivery requiring a medio-lateral episiotomy might benefit 
from antibiotic prophylaxis as standard of care. Reducing risk of anaemia after CS 
delivery can be achieved by prenatal iron supplementation and by spinal rather 
than general anaesthesia.
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